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Abstract
Glycation is a non-enzymatic reaction with reactants including a
reducing sugar and a free amino containing molecule such as protein,
amino acids, DNA, RNA and lipids. In the initial phase of glycation, the
carbonyl group of the reducing carbohydrate condenses with the free amino
groups on the target biomolecule to form reversible glycosylamines, which
are then converted to more stable Amadori products. Once formed, these
Amadori products can with time undergo dehydration, cyclization, oxidation,
and rearrangement to form a polymorphic group of compounds collectively
referred to as Advanced Glycation Endproducts (AGEs). The accumulation
of AGEs in vivo has been implicated as a major pathogenic process in
diabetic complications including diabetic cataract formation, retinopathy and
neurological diseases, as well as other health disorders, such as
Alzheimer’s disease (AD).
Chapter one reviewed the chemistry of glycation and the formation of
AGEs in a mechanical perspective. The role of AGEs in the pathogenesis of
diabetic nephropathy, diabetic neuropathy, diabetic retinopathy and
Alzheimer’s disease were considered. Here we also reviewed the potential
inhibitors against glycation published to date, focusing on some novel
potential AGE inhibitors such as zinc and gold nanoparticles.
The purpose of the study described in chapter two was to investigate
the susceptibility of the amine groups of melamine to glycation by milk

sugars and sugar metabolites. Dairy products adulterated with melamine
have been recently blamed for the death of at least several infants and the
sickening of countless children in China. The presented study described the
non-enzymatic glycation of melamine with milk sugar D-galactose and
several

sugar

metabolites

including

methylglyoxal,

glyoxal

and

DL-glyceraldehyde. The chemical structures of melamine AGEs were
characterized by electrospray mass spectrometry. The factors influencing
the rate and extent of melamine’s glycation were also evaluated.
The third part of the dissertation described a study on anti-glycation
effect of gold nanoparticles (GNPs). In this study we showed that certain
sizes of spherical GNPs exhibit an inhibitory effect on the formation of AGEs
when Bovine Serum Albumin (BSA) was glycated by D-ribose. A
combination of UV spectrometry, HPLC and circular dichroism showed that
only GNPs with size ranging from 2nm to 20nm inhibited the formation of
BSA AGEs. The inhibition effect of GNPs was correlated to the overall
surface area of nanoparticles in the solution. GNPs with higher surface
areas were found to be better inhibitors of glycation, whereas those with low
surface areas were less effective inhibitors. The inhibitory effect of GNPs on
non-enzymatic glycation reactions may be due to the covalent bonding
between gold atoms on the surface of GNP and ε amino groups of L-lysine
residue on protein.
In chapter four, we evaluated the effect of UVC radiation on glycation of

Human Serum Albumin (HSA). In this study, we found that exposure to UVC
radiation accelerated the glycation level of HSA and promoted the formation
of AGEs, which may be stimulated by the generation of ROS by UVC
radiation. A combination of several analytical methods including UV
spectrometry, HPLC, and MALDI-TOF were used to evaluate the glycation
level of HSA at 37 °C under neutral pH in the presence of D-glucose in vitro.
This study warrants further investigation as there have been few reports on
the correlation between the UVC radiation of proteins and their enhanced
glycation by a reducing sugar.
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Preface
This dissertation presents one review article and two scientific projects.
All three manuscripts focus on the chemistry of glycation, a non-enzymatic
reaction which plays an important role in the pathogenesis of diabetic
complications including atherosclerosis, renal failure and cardiovascular
disease. Chapter one reviews the mechanism and biological effects of
glycation. Chapter two describes the glycation reaction of melamine with
sugars found in milk and their metabolic products. Chapter three presents
the study of gold nanoparticle’s anti-glycation property when bovine serum
albumin is glycated by D-ribose. Chapter four presents the study on
enhancement effect of UVC radiation on the glycation level of HSA.
The dissertation is written in manuscript format. Manuscript two has
been accepted by Bioorganic Chemistry in September 2012 and is
expected to be published in the journal’s latest issue. Manuscript one was
prepared according to the format guidelines of Biochimica Biophysica Acta
while manuscript three and manuscript four were prepared according to the
format guidelines of Analytical Biochemistry.
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Abstract
Glycation is a non-enzymatic reaction between reducing sugars and
amino groups in proteins, nucleic acids and lipids. The final products of this
reaction are a polymorphic group of compounds collectively referred to as
Advanced Glycation Endproducts (AGEs). The gradual built-up of AGEs in
body tissues plays an important role in the pathogenesis of diabetic
complications including atherosclerosis, renal failure and cardiovascular
disease. Recent studies suggest that AGEs selectively bound to AGE
receptors found in several cell types, many of which are affected by
diabetes. The interaction of AGEs to these receptors triggers the release of
pro-inflammatory molecules and free radicals, inducing oxidative cellular
dysfunction. The intracellular uptake of AGEs also alters cell signaling and
gene expression that contribute towards the pathology of diabetic
complications. This article reviews the chemistry of glycation and the
formation of AGEs in a mechanical perspective. The role of AGEs in the
pathogenesis of diabetic nephropathy, diabetic neuropathy, diabetic
retinopathy and Alzheimer’s disease are considered. Here we also review
the potential inhibitors against glycation published to date, focusing on
some novel potential AGE inhibitors such as zinc and gold nanoparticles.

Key words: glycation; AGEs; diabetes; ROS
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1.1 Introduction
The Non-enzymatic reaction between the carbonyl group of a reducing
sugar and the amino containing molecule such as protein, peptide or amino
acid was first studied under defined conditions by Louis Camille Maillard in
1912. Ever since its description in early 1900s, the Maillard reaction has
continued to be a topic of research interest. For researchers in nutrition
science, harnessing the Maillard reaction has allowed for controlling food
flavor, food aroma, food coloring, and food texture. In addition to its benefits,
the Maillard reaction occurring during food processing also results in the
loss of protein quality and the formation of harmful compounds with
mutagenic, carcinogenic and genotoxic properties (1-3).
During the 1970s and 1980s, researchers in clinical medicine realized
that this process also occurs slowly in vivo. Subsequently, Maillard reaction
in vivo was termed glycation, distinguished from enzymatic glycosylation.
The final products of this reaction are a polymorphic group of compounds
collectively referred to as Advanced Glycation Endproducts (AGEs). The
gradual built-up of AGEs in body tissues plays an important role in the
pathogenesis of diabetic complications including atherosclerosis, renal
failure and cardiovascular disease. Glycation is also found to be related to
other health disorders such as Alzheimer Diseases (AD) and normal aging
(4-6).
Intracellular hyperglycemia can induce the formation of glucose-derived
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dicarbonyl molecules such as glyoxal, methylglyoxal and 3-deoxyglucosone.
These intracellular dicarbonyls, also called AGE precursors, are much more
reactive comparing to D-glucose due to their lack of cyclic structure and
comparatively smaller size. AGE precursors glycate with amino groups of
both intracellular and extracellular proteins at a much faster rate than
D-glucose, leading the accumulation of AGEs. These AGEs specifically
binds to a certain groups of cell surface receptors (RAGEs), inducing
receptor-mediated production of reactive oxygen species (ROS), finally
resulting in oxidative cellular dysfunction (3, 7). AGEs such as glyoxal lysine
dimer (GOLD) and methylglyoxal lysine dimer (MOLD) are responsible for
protein crosslinking on longest-lived extracellular proteins such as collagen
and elastin. Such proteins provide strength and flexibility to tissues, and do
not get recycle very often. Glycation and crosslinking gradually change the
property and function of these proteins, reduce their flexibility and elasticity,
and increase their stiffness as well. This process has been implicated as
strong contributors to many progressive diseases of aging, including
vascular diseases, stiffness of joints, arthritis and kidney failure (4-6).
Both synthetic compounds and natural products have been found to be
inhibitors against the formation of AGEs. These glycation inhibitors are
proposed to block the formation of intermediate Amadori products, or break
the crosslinking of proteins. Their classification and corresponding inhibition
mechanism will be discussed later in this article.
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1.2 The chemistry of glycation
Glycation is a non-enzymatic browning reaction that involves a series of
steps with the reactants typically including a reducing sugar and a free
amino containing molecule. The progress of the reaction includes three
distinguishable phases: the initial stage, the intermediate stage and the late
stage. In the initial phase of glycation, the carbonyl group of a reducing
carbohydrate condenses with the free amino group on a protein or other
amino containing molecule to form reversible glycosylamine, which is then
converted to more stable Amadori products. Under appropriate condition,
these Amadori products could degrade to more reactive dicarbonyls such as
methylglyoxal, glyoxal and glyceraldehyde. These intermediates are
responsible for most of the AGE formation due to their high reactivity. In the
late stage of glycation, the Amadori product itself could with time undergo
dehydration, cyclization, oxidation, and rearrangement to form AGEs.
Meanwhile, the AGE precursors formed from the intermediate stage of
glycation such as methylglyoxal will in turn interact with protein or other
amino containing molecules to produce AGEs at a much higher reaction
rate comparing to reducing sugars.
1.2.1. Initial stage: formation of Amadori products
In the initial phase of glycation, the nitrogen atom of a terminal 𝛼-amino
group or of the ε-amino group on lysine or arginine residue covalently
condenses with the carbonyl group of a reducing sugar by nucleophilic
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attack. The product of this reaction contains an unstable aldimine structure
named Schiff base. The formation of Schiff base is reversible due to the
unstable property of aldimine functional group. Schiff base intermediate can
then undergo Amadori rearrangement to produce a relatively stable
ketosamine structure, referred to as Amadori product (See figure 1).
Formation of Amadori product from Schiff base is much faster than the
reversed reaction so Amadori adducts tend to accumulation on proteins.
This process is thought to be facilitated by localized acid-base catalysis if
there is a histidine or lysine side chain about 5 Å from the target amino
residue (8).
1.2.2. Intermediate stage: formation of AGE precursors
AGE precursors are formed in vivo via two major pathways: 1) the
fragmentation of Amadori products or Schiff base, and 2) the metabolic
degradation of D-glucose. The physiologically relevant D-glucose is one of
the least reactive reducing sugars in protein glycation (9). Under
physiological condition, over 90% of D-glucose is in cyclic confirmation
which cannot be a target of the nucleophilic attack by a primary amino group.
However, other sugars and dicarbonyl compounds, many of which are found
intracellular such as glyoxal (Gly), 3-deoxyglucosone (3-DG) and
methylglyoxal (MG) participate in glycation at a proportionally faster rate (10,
11). Gly is formed from several reactions such as the oxidative
fragmentation of Schiff base via the Namiki pathway (12, 13), glucose
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auto-oxidation catalyzed by metal (Wolff pathway) or lipid peroxidation via
the Acetol pathway (14, 15). 3-DG is produced from non-oxidative
fragmentation and hydrolysis of Amadori product. 3-DG also forms from
fructose-3-phosphate, an intermediate of the Polyol pathway in which
glucose is reduced to sorbitol by aldose reductase. Further degradation of
3-DG generates methylglyoxal and glyceraldehyde (GA) by retro-aldol
condensation (16, 17). Methylglyoxal is found to be one of the most reactive
glycation agents, and could react with different amino acids including lysine
and arginine to generate dicarbonyl-derived AGEs. MG could also alter the
secondary structure of a protein, resulting in the loss of its function (18, 19).
A summary of the sources of these reactive carbonyl species are shown in
figure 2.
The increase in the concentration of reactive carbonyl compounds from
glycoxidation, lipoxidation or the degradation of Schiff base/Amadori
adducts will lead to carbonyl stress (20, 21), a situation that aggravates the
modification of proteins and prompts the formation of AGEs. Figure 3 is a list
of chemical structures of currently well-defined AGE dicarbonyl precursors
and their interactions with glycated proteins.
1.2.3. Late stage: formation of AGEs
AGEs are a group of heterogeneous compounds including fluorescent
crosslinking structures such as pentosidine, non-fluorescent crosslinking
substances such as glyoxal lysine dimer (GOLD) or methylglyoxal lysine
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dimer (MOLD), and non-fluorescent, non-crosslinking compounds such as
Nε-carboxymethyl lysine (CML). AGEs are produced both in vitro and in vivo
via several pathways, including direct degradation of Amadori products or
Schiff base, protein modification by dicarbonyl compounds and reactions
between Amadori products and AGE precursors.
One of the major consequences of protein being modified by active
dicarbonyl glycation agents is the formation of protein cross-links, a
situation that is related to several diabetic complications. Reactions of
dicarbonyl compounds with lysine and arginine residue or with Amadori
intermediate are involved in the formation of many AGE crosslinking
structures which exhibit fluorescence absorbance (Figure 4). Among these
compounds, pentosidine from the glycation of ribose has been determined
in many tissues such as lens proteins and skin collagens (22). Pentosidine
can also be formed from several more reactive carbohydrate intermediates
including 3-DG and fructose. It has been recently proposed as an index for
evaluating tissue damage under glycation condition (23).
Although fluorescent crosslinking AGEs are important biomarkers of
hyperglycemia condition due to their easy of detection, these structures are
account for only a small portion of protein crosslinks which is about 1% in
physiological condition (24). On the other hand, non-fluorescent crosslinking
AGEs are the major contribution to in vivo protein-protein crosslinks. A
group of most well defined crosslinking structures are imidazolium
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crosslinks including glyoxal-derived AGE glyoxal-lysine dimer (GOLD) and
methylglyoxal-derived AGE methylglyoxal-lysine dimer (MOLD) (25, 26).
Both of these structures are found in human lens protein and human serum.
(27-29). Glyoxal and methylglyoxal could irreversibly modify the ε-amino
group of lysine residues in protein under physiological condition to form
these

imidazolium

compounds

which

are

responsible

for

protein

crosslinking.
The third class of AGEs is non-fluorescent, non-crosslinking structures,
which act as biological receptor ligands to initiate cellular signaling and
induce tissue oxidation stress. These compounds could also perform as
precursor of protein crosslinks. The chemical structures of some of the most
important and well-studied non-crosslinking AGEs including pyrraline,
1-carboxyalkyl lysine and imidazolone A and B are shown in figure 5.
3-DG rapidly reacts with lysine residues of a protein to form pyrraline.
Though pyrraline itself is not a crosslink structure, it may cause crosslinks
between proteins when its aldehyde group forms a Schiff base with another
amino group, resulting in lysine-lysine or lysine-arginine crosslinking in vivo.
Imidazolone is derived from reaction of dicarbonyl compounds with the
guanidino group of an arginine residue.
AGEs such as Nε-carboxymethyl lysine (CML) and Nε-carboxymethyl
lysine (CEL) with a carboxyalkyl group attached to the ε-amino group of an
amino acid are found in vivo. CML is known as one of the most well
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characterized AGEs which is used as a biomarker for long-term protein
damage in diabetes and oxidative tissue abnormality. CML can be produced
through different pathways including glycation and oxidation reactions (22,
30, 31), resulting in its wide distribution in a variety of tissues such as serum,
skin collagen and kidney.
CML is produced through four major pathways shown in figure 6: 1)
oxidative cleavage of Amadori product 2) Schiff base degradation through
Namiki pathway (32); 3) oxidation of ascorbic acid (33) and 4) autoxidation
glycosylation with lysine and glyoxal (32). The oxidative degradation of
Amadori adducts is thought as the major source of CML formation (25, 34).
Under physiological condition, CML is found to be produced mainly from
fructoselysine, an Amadori intermediate derived from fructose and lysine.
The Schiff base can undergo degradation via Namiki pathway to form active
carbonyl compounds such as glyoxal and its corresponding imine analog,
which are responsible for the formation of CML. The other CML precursor
formed via Namiki pathway is aminoaldehyde. Aminoaldehyde could oxidize
to CML by any of the oxygen reactive species present in the glycation
system, or by oxygen under metal catalysis. Other sources of CML
formation include the oxidation of ascorbic acid derived from glucose and
direct condensation of glyoxal with the ε-amino group of lysine residues in
proteins.
1.3. Biological effects of glycation
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Non-enzymatic glycation has been thought to play an important role in
the pathogenesis of diabetic complications including cataract formation,
renal failure and cardiovascular disease. Glycation is also approved to be
related to other health disorders such as Alzheimer’s disease (AD),
atherosclerosis and normal aging. Most of the effects of glycation which
lead to chronic complications are due to AGE accumulation on long-lived
proteins such as collagen and lens crystallins. In the meantime, glycation
can induce the formation of reactive oxidation species (ROS), causing
oxidation stress and tissue damage (35, 36).
1.3.1 Physiological defense system against glycation
There are several defense systems occurring physiologically against
the deleterious effects of AGE, including enzymes such as aldose reductase，
which inhibit the formation of AGE precursors or antioxidants such as
glutathione which reduce the production of reactive oxidative species.
Aldose reductase is a NADPH-dependent enzyme that catalyzes the
degradation of dicarbonyl AGE intermediates including MG and 3-DG
(37-39). Most recently, fructoselysine, an Amadori intermediate derived from
fructose and lysine, was found to be phosphorylated by human
fructosamine-3-kinase (FN3K) and spontaneously degradation afterwards
(40). The glyoxalase system catalyzes the conversion of methylglyoxal to
D-lactic acid by glyoxalase I and glyoxalase II. This system is present in the
cytosol and mitochondria of cells and has a wide distribution in living
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organisms (41, 42). Another natural common defense mechanism is
glutathione (GSH) system. GSH is an antioxidant, preventing oxidative
damage to tissues caused by reactive oxidative species such as peroxides
and free radicals, whose formations are prompted by glycation. GSH also
facilitated the rearrangement of methylglyoxal to D-lactate in the glyoxalase
pathway (43).
1.3.2 AGE mediated cell-signaling
Intracellular accumulation of AGEs damages target cells through
receptor-mediated pathway, in which the glycated plasma proteins bind to
AGE receptors on the cell surface, inducing cell signaling and oxidation
stress (see figure 7). Several AGE binding proteins have been identified
such as RAGE, the AGE receptor complex (AGE-RG) and macrophage
scavenger receptor (44-46), many of which play a critical part in the
pathology associated with AGE related complications.
In endothelial cell system, plasma proteins modified by AGEs act as
ligands to AGE receptors found on the surface of the cell. This process
activates intracellular transducers and leads to the changes in gene
expression.

A

rise

in

the

expression

of

pro-inflammatory

and

pro-coagulatory molecules was found in endothelial cell when it was
exposed to high glucose (47-50). RAGE is a member of the immunoglobulin
receptor family. Pro-inflammatory NF-κB pathway is thought to be one of the
major targets of RAGE. The activation of the pathway is related to several
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inflammatory diseases in diabetes. In addition, NF-κB in turn elevates
RAGE expression, establishing a positive feed-back cycle. In summary, the
intracellular accumulation of AGE results in the increase of RAGE ligands,
activating NF-κB pathway and lead to chronic inflammation.
Additionally, AGE receptors are found on the surface of macrophage
and mesangial cell. Binding of AGE ligands to the receptor induces the
formation of reactive oxygen species (ROS) including peroxyl, superoxide
anions, hydroxyl radicals and hydrogen peroxides (structures seen in figure
8). As discussed previously in this article, the abnormal excess of ROS
under hyperglycemia conditions originate from several mechanisms
including the degradation of glycation intermediates, the by-production of
carbonyl AGE precursors, and cellular oxidant stress triggered by RAGE.
The abnormal accumulation of ROS caused by hyperglycemia is known to
mediate the progression of several chronic complications due to the
impaired antioxidant defense system. Such situation is defined as oxidative
stress. Pathways for the generation of ROS which lead to oxidative stress
are summarized in figure 9. The rise in the oxidant level in a living organism
can cause damage to various cell components and triggers the activation of
certain cell signaling pathways, resulting in pathological changes in gene
expression.
1.3.3 AGE induced protein dysfunction
Several intracellular proteins modified by glycation are found to have
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altered activities and stabilities. One example is serum albumin, the most
abundant protein in blood plasma which exhibits a broad range of
physiological functions such as catalytic activities. Serum albumin can
catalyze the hydrolysis of esters, showing an esterase-like activity. However,
its enzymatic activity is impaired drastically when the protein is glycated by
methylglyoxal. Since a lysine residue of the protein has been suggested as
the catalytic center, the loss of the protein’s esterase activity is thought to be
related to the modification of this lysine residue by glycation agents (51).
Another example of dysfunctional AGE modified protein is proteases, a
class of enzymes which degrade polypeptides. The catalyze sites of this
enzymes include cysteine and histidine, both of which can be glycated by
methylglyoxal, resulting in the loss of enzymes’ activity (52).
AGE formation does not only alter the activity of intracellular proteins,
but affect the functional properties of important molecules on extracellular
matrix such as various types of collagens. Collagen is the main components
of connective tissue, responsible for skin elasticity, blood vessel strength
and tissue regeneration. This type of proteins has a comparatively long
biological half-life and is exposed to extracellular glucose whose level is
considerably higher than that inside the cell. Collagen can react with other
collagen molecules through protein crosslinking by some typical AGE
structures including methylglyoxal lysine dimer (MOLD) and glyoxal lysine
dimer (GOLD). Such crosslinking structures can be gradually built up during
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normal aging and are accumulated much faster under hyperglycemia
condition. As a result, the formation of MOLD and GOLD plays a critical role
in the pathologenesis of vascular stiffening and atherosclerotic lesions (17).
1.4 AGEs and diseases
The accumulation of AGEs has been implicated as strong contributors
to many progressive diseases including diabetic complications, aging and
Alzheimer’s disease. AGEs play a role in the pathogenesis of such health
disorders through three major mechanisms: 1) AGE modified plasma
proteins could bind to AGE receptors on the surface of the cell, activate cell
signaling and lead to the production of ROS and inflammatory factors; 2)
intracellular proteins, specifically catalytic proteins, could lose their function
and stability if the activate site is glycated by AGE precursors; 3) proteins on
the extracellular matrix such as collagen could crosslink with other matrix
components, leading to the loss in their function.
1.4.1 AGEs and diabetic complications
1.4.1.1 Diabetic nephropathy
Diabetic

kidney

disease

is

one

of

the

major

microvascular

complications of diabetes. The hyperglycemia related mechanisms of
diabetic nephropathy can be explained in three pathways. First, by binding
to signaling cell surface receptors, AGEs can activate protein kinase C
(PKC) which plays a center role in the pathogenesis of diabetic nephropathy.
Second, binding of AGEs to their receptors can increase the expression of
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several transcription factors and enhance the formation of ROS. Third, the
intracellular AGEs also initiate cell signaling events which alter the
expression of extracellular matrix proteins including type I and type IV
collagens. Meanwhile, AGEs can form crosslinking structures with collagens,
causing altered cell adhesiveness and capillary permeability.
PKC is an intracellular signaling kinase which can be activated by the
binding of AGEs with RAGE. The activation of PKC will lead to endothelial
dysfunction resulting in altered blood flow and capillary permeability. PKC
can also induce the generation of pro-inflammatory factors such as NF-κB
and lead to local tissue inflammatory (53, 54). Hyperglycemia condition
promotes the generation of ROS during or after the formation of AGEs.
There is considerate in vitro study suggesting the involvement of ROS in the
pathogenesis of renal injury. The generation of ROS is coupling with the
biological alteration of tubular cells with loss of epithelial cell adhesion (55).
Moreover, the balance of nitroso-redox can be disturbed by the formation of
ROS when the radicals inactive relaxing nitric oxide and cause hypertension.
Besides the activation of PKC and the up-modulation of ROS, the
accumulation of AGEs causes the increased synthesis of extracellular
matrix and decreased expression of its degrading enzymes, leading to the
polymerization and expansion of extracellular matrix proteins (56-58).
1.4.1.2 Diabetic neuropathy
The symptoms of diabetic neuropathy often develop slowly over years,
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including the loss of sensation, nausea, deep pain in legs and feet. The
pathology can be characterized by progressive nerve fiber lose caused by
long-term high blood sugar level in diabetes. The precise mechanisms
underlying diabetic neuropathy is unclear, however most recent study
suggests that the loss in nerve fiber can be caused by multiple pathways
including the enhanced polyol pathway under hyperglycemia condition, the
increased protein modification by AGEs and the up-regulated oxidation
stress.
In polyol pathway, glucose is degraded to sorbitol by aldose reductase.
This process can be up-regulated under hyperglycemia condition, causing
increased consumption of NADPH and reduced formation of glutathione.
The impaired synthesis of glutathione will then cause vascular insufficiency
and degeneration of nerve fibers (59). The activation of polyol pathway also
suppresses the activity of protein kinase C, and eventually elicits reduced
nerve blood flow and decreased nerve conduction (60). Meanwhile, the
binding of AGEs to their receptors has been found to induce oxidative stress,
result in over expression of pro-inflammatory genes, and exaggerate
neurological dysfunction, including altered pain sensation. The AGE-RAGE
interaction can also activate the formation of extracellular matrix proteins.
AGEs in terns covalently bond to these proteins to form crosslink structures,
and lead to the development of vascular abnormalities, such as thickening
of capillary basement membrane.
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1.4.1.3 Diabetic retinopathy
Many in vitro and in vivo studies showed that AGEs play a significant
pathogenic part in diabetic retinopathy, when the retinal microvascular
becomes dysfunctional progressively, resulting in damage to the retina of
the eye (61). The accumulation of AGEs is proposed to participate in the
progression of the disease via three pathways. First, the binding of AGEs to
their receptors induce the formation of vascular basement membrane
proteins. These proteins are then cross-linked by certain species of AGEs,
resulting in basement membrane thickening and the breakdown of the inner
blood-retinal barrier (62, 63). Second, AGEs-RAGE binding inappropriately
initializes intracellular signaling, cause abnormal expression of transducers
or growth factors, which result in the failure of endothelial cells. Third, retinal
vascular endothelia cells show disturbed nitric oxide expression when
exposed to high concentration of AGEs, which may be a cause of capillary
closure and retinal ischemia.
Besides diabetic retinopathy, the cataract formation is another major
complication

developing

gradually

in

diabetes

disorder.

Under

hyperglycemia condition, there is an increased production of highly reactive
dicarbonyl compounds such as methylglyoxal and glyoxal. These molecules
not only act as AGE precursors but also cause AGE crosslinks and protein
aggregations on crystallins, leading to the formation of cataract (64-66).
Other study suggests that oxidation stress, which is upgraded by glycation,
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can promote the formation of cataract as well.
1.4.2 AGEs and Alzheimer’s Diseases
Alzheimer’s disease (AD) is an age-related chronic complication which
severely affects patients’ memory and behavior in their late life. The causes
of such disease include early stage triggering events and late stage
inflammation and neurodegeneration. Several studies suggest that the
formation of AGEs plays an important role in the pathogenesis of AD.
The deposition of β-Amyloid (Aβ) in the cerebral cortex is one of the
major pathological features of AD. Aβ peptides contain 39 to 43 amino acid
residues and are found overproduced in AD brains. These peptides are
thought to be one of the most important contributors to neurodegeneration
(67, 68). Solid evidence revealed that extensive protein crosslinking and the
increased production of ROS, inflammatory factors and reactive dicarbonyl
compounds are responsible for AD characteristics including the Aβ deposit
(69). Meanwhile, all the above mentioned chemical processes are related to
glycation and AGEs, whose formation is found to be accelerated in AD.
It has been suggested that the accumulation of AGEs is involved in the
pathogenesis of AD through two major mechanisms including AGE-RAGE
interaction and protein-Aβ crosslinking. As described in the previous chapter,
AGE modified proteins can interact with cell surface receptors such as
RAGE, and trigger a serial of cellular signaling pathways. Besides AGEs, Aβ
is found to be another ligand of RAGE. The interactions of AGEs and Aβ
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with RAGE elicit the production of ROS and pro-inflammatory factors. The
generation of these molecules will then cause oxidative stress and
inflammatory,

subsequently

leading

to

neuronal

dysfunction.

The

accumulation of AGEs is also responsible for protein-Aβ crosslinks, a major
cause to neurodegeneration in AD. Such binding down-regulates the
expression of genes involved in Aβ clearance, resulting in Aβ accumulation.
1.4.3 AGEs and aging
Hyperglycemia is shown to be correlated to several age-related
diseases and the controlling of such condition prolonged life span in
experimental animals. Hyperglycemia induces the formation of AGEs when
protein is glycated by reducing sugars or active dicarbonyl compounds.
AGEs up-regulate oxidative stress and inflammation, cause crosslinks on
long lived protein such as extracellular matrix and vascular basement
membrane, and reduce the clearance of harmful protein aggregations. Thus
AGEs play a significant role in the pathogenesis of several diseases across
different organ systems, many of which are age-related. AGEs interact with
their receptors and trigger the induction of ROS and pre-inflammatory
factors. AGEs and AGE receptors are found in different cell types including
smooth muscle cells, endothelium and mono nuclear cells. Such wide
distribution of these compounds causes the chronic damage to virtually
every tissue in the body. Meanwhile, AGEs elicit protein cross-links and
affect most on tissues composed with long-lived proteins such as skin,
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skeletal muscle, heart, arteries and lens. AGE-mediated protein crosslinking
in connective tissues causes the loss in their elasticity and flexibility,
resulting in skin aging, hypertension and cataract formation.
1.5 Inhibitors against AGE formation
Since non-enzymatic glycation of proteins is a major contributor to the
pathology of diabetes and other diseases including AD, the inhibitors to
prevent the formation of AGEs have been extensively investigated and a
number of potential AGE inhibitors have been proposed over years. A
schematic of in vivo glycation reactions is shown in figure 10. On this
scheme are also common targets for AGE inhibition which are labeled by
circled letters from A to F. Type A and type B inhibitors prevent the formation
of Amadori product at the initial stage of glycation by competing with
glycation agents (type A) or reacting with reducing sugars (type B) (70-72).
Other types of inhibitors (type C1 and C2) disturb glycation mechanisms
such as Wolff pathway and Namiki pathway, enhance antioxidant activity,
and reduce the production of dicarbonyl AGE precursors. Type D drugs
interact with reactive dicarbonyl compounds such as methylglyoxal and
glyoxal, preventing their binding to protein (73, 74). Comparing to class D,
class E compounds directly act on Amadori adducts, and trap it from further
modification (75). Instead of preventing AGE formation, drugs in F group
reduce AGE toxicity by breaking protein-AGE cross-linking. There are also
numbers of novel AGE inhibitors such as zinc and nanoparticles, whose
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inhibition mechanisms are still under investigation.
1.5.1. Carbonyl compounds scavengers
The first and most well-known synthetic glycation inhibitor is
aminoguanidine (AG) (76), whose structure can be found in figure 11.
Aminoguanidine prevents the formation of AGEs by reacting with reactive
dicarbonyl compounds such as methylglyoxal and glyoxal, hindering the late
stage of glycation. Several in vivo studies demonstrated that AG retarded
the development of several diabetes related complications including renal
failure and cataract formation (77). Unfortunately, AG showed considerable
toxicity to human body during clinical trial, thus structural modification on the
compound is required to reduce its toxicity. Pyridoxamine (PM), one of the
vitamin B complexes, is another potent carbonyl scavenger which showed
better inhibitory effect on reducing the glycation level in bovine serum
albumin model (78). PM inhibits the formation of AGEs not only by trapping
the reactive dicarbonyl AGE precursors, but by blocking the oxidative
degradation of the Amadori intermediates as well, preventing it from further
modification by reducing sugars (79).
1.5.2 AGE breakers
Cell tissue constantly exposed to AGEs tent to lose its function due to
protein crosslinking. Recently, a few AGE breakers have been discovered to
combat deleterious protein cross-links. Their structures are shown in figure
12. This class of anti-glycation agents provides a potential new therapeutic
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approach especially for diabetic cardiovascular disease. Patients who
received alagebrium chloride (ALT-711), one of the most well studied AGE
breakers, showed significant reduction in arterial pulse pressure (80).
Another prototypic protein cross-link breaker is N-phenacylthiazolium
bromide (PTB). PTB reacts with AGE-induced protein aggregates and
covalently cleaves protein crosslinking structures (81).
1.5.3 Dietary antioxidant
A dietary antioxidant is considered to be relatively safe for human
consumption comparing to above mentioned synthetic compounds. The
accumulation of AGEs induces the formation of ROS, leading to cell
dysfunction and tissue damage. Dietary antioxidants are substances found
in food that decrease the damage of ROS, and restore physiological
function in humans. Vitamin C and vitamin E, for instance, both prevented
the formation of AGEs in experimental models. Treatment of diabetic rats
with these antioxidants resulted in a reduced plasma lipid peroxidation level.
The study also showed that vitamin E has a potent to restore nerve system
by reversing nerve conduction velocity deficits (82).
1.5.4 Novel AGE inhibitors
Besides synthetic anti-glycation

agents and

traditional dietary

substances which reduce the damage of ROS, some novel AGE inhibitors
have also been proposed recently, including zinc and gold nanoparticles
(GNP). In a recent in vitro study, human serum albumin treated with different
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concentrations of zinc showed lower glycation level comparing to control
experiment, suggesting that zinc inhibited the formation of AGEs. In this
study, a combination of analytical methods was used to evaluate the level of
protein glycation. Moreover, the treatment of zinc not only reduced the
formation of glycation products, but also retained protein’s secondary
structure, an observation which was confirmed by circular dichroism. Zinc
was proposed to inhibit glycation by binding to the reactive sites on the
protein and preventing sugar’s non-enzymatic condensation with these sites
(83). GNP is another substance which showed anti-glycation activity as well
as satisfying bio compatibility. In one study, spherical gold nanoparticles
(GNPs) with a diameter of 2 nm showed an inhibition effect on the formation
of AGEs when human serum albumin was glycated with DL-glyceraldehyde.
The inhibitory effect of GNPs on non-enzymatic glycation reactions may be
due to the covalent bonding between gold atoms on the surface of GNP and
ε amino groups of L-lysine residue on protein. As GNP is highly
biocompatible and water soluble, an insight of its anti-glycation effect and its
inhibition mechanism on the formation of AGEs might lead to a novel
therapeutic application of GNP on reducing AGE related complications (84).

1.6. Conclusion
In conclusion, glycation is a non-enzymatic reaction with reactants
including a reducing sugar and a free amino containing molecule such as
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protein, amino acids, DNA, RNA and lipids. In the initial phase of glycation,
the carbonyl group of the reducing carbohydrate condenses with the free
amino groups on the target biomolecule to form reversible glycosylamines,
which are then converted to more stable Amadori products. Once formed,
these Amadori products can with time undergo dehydration, cyclization,
oxidation, and rearrangement to form a polymorphic group of compounds
collectively referred to as Advanced Glycation Endproducts (AGEs). The
accumulation of AGEs in vivo has been implicated as a major pathogenic
process in diabetic complications including diabetic cataract formation,
retinopathy and neurological diseases, as well as other health disorders,
such as aging and Alzheimer’s disease (AD).
AGEs play a role in the pathogenesis of such health disorders through
different yet complicated cellular mechanisms including ligand induced cell
signaling which causes oxidative stress and inflammation; protein
dysfunction due to modification on the active site by glycation; and protein
crosslink which leads to its denaturation. The inhibitors to prevent the
formation of AGEs have been extensively investigated based on these
pathways. The most promising glycation inhibitors include amino-guanidine
and pyridoxamine which trap the active dicarbonyl molecules and prevent
the formation of AGEs. Some novel anti-glycation substances such as zinc
and gold nanoparticles have also been proposed recently.
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Figure 1. The initial stage of glycation resulting in the formation of a Schiff
base and an Amadori product.
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Figure 2. In vivo sources of dicarbonyl glycation precursors which are
responsible for the formation of AGEs and carbonyl stress (85).
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Figure 3. Chemical structures of currently well-defined AGE dicarbonyl
precursors (glyoxal, 3-deoxy-glucosone and methylglyoxal), and their
interactions with glycated proteins (86).

35

Figure 4. AGE crosslink structures formed under physiological condition
which exhibit fluorescence absorbance. [Lys] indicates to lysine residue and
[Arg] indicates to arginine (5).
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Figure 5. Chemical structures of some of the most important and
well-studied non-crosslinking AGEs including pyrraline, 1-carboxyalkyl
lysine and imidazolone A and B. [Lys] indicates to lysine residue and [Arg]
indicates to arginine (5).
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Figure 6. Pathways for the formation of Nε-carboxymethyl lysine in vivo (87).
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Figure 7. Intracellular accumulation of AGEs damages target cells through
receptor-mediated pathway, in which the glycated plasma proteins bind to
AGE receptors on cell surface, inducing cell signaling and oxidation stress
(56).
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Figure 8. Structures of reactive oxygen species (ROS).
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Figure 9. Pathways for the generation of ROS which lead to oxidative stress
(85).
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Figure 10. Schematic of in vivo glycation reactions and common targets for
AGE inhibition in the pathways (87).
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Figure 11. Structures of some synthetic anti-glycation agents which act as
dicarbonyl compound scavengers (88).
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Figure 12. Structures of some typical AGE breakers which reduce the
damage of glycation (88).
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Abstract

Melamine (1,3,5-triazine-2,4,6-triamine) is employed in the manufacture of
plastics, laminates and glues, yet, it has been found sometimes added
illegally to dairy products to artificially inflate foods’ protein content. In 2008,
dairy products adulterated with melamine were blamed for the death of
several infants in China, a situation that forced Beijing to introduce stricter
food safety measures. The objectives of this study were threefold: 1) to
investigate, using UV and fluorescence spectrometry, the susceptibility of
the amine groups of melamine to glycation with D-galactose, D-glucose and
lactose, sugars commonly found in milk, 2) to study the rate and extent of
melamine’s glycation with methylglyoxal, glyoxal and DL-glyceraldehyde,
three highly reactive metabolites of D-galactose, D-glucose and lactose,
and 3) to characterize, using HPLC and mass spectrometry, the Advanced
Glycation Endproducts (AGEs) of melamine with sugars found commonly in
milk and their metabolites. Incubation of D-galactose, D-glucose and
lactose with melamine revealed that D-galactose was the most potent
glycator of melamine, followed by D-glucose, then lactose. Methylglyoxal,
glyoxal, and DL-glyceraldehyde glycated melamine more extensively than
D-galactose, with each yielding a broader range of AGEs. The
nonenzymatic modification of melamine by sugars and sugar-like
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compounds warrants further investigation, as this process may influence
melamine’s toxicity in vivo.
Keywords: melamine; glycation; D-galactose; methylglyoxal; AGEs

1.0.

Introduction

In 2008, many dairy products in China were found to be adulterated with the
chemical melamine, a situation that contributed to the death and
hospitalization of children and a massive recall of many food products (1 - 5).
The adulteration of food products with melamine unfortunately continues to
this day in China, despite the government’s ongoing efforts to halt this
practice.
Melamine is an organic base with a 1,3,5-triazine backbone. That is
essentially a trimer of cyanamide with three amino groups attached to its
hexagonal structure (see figure 1). The three amino groups suggest that
melamine should be a target for nonenzymatic glycation by the Maillard
reaction.
The Maillard reaction is a non-enzymatic browning reaction that involves a
series of steps with the reactants typically including a reducing sugar and a
protein. In the initial phase of the Maillard reaction, the carbonyl group of the
reducing carbohydrate condenses with the free amino groups on the protein
to form reversible glycosylamines, which are then converted to more stable
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Amadori products. Once formed, these Amadori products can with time
undergo dehydration, cyclization, oxidation, and rearrangement to form a
polymorphic group of compounds collectively referred to as Advanced
Glycation Endproducts (AGEs) (6 - 8).
Ever since its description in 1912, the Maillard reaction has continued to be
a topic of research interest. One reason for this focus on the Maillard
reaction is that it cuts across several disciplines with nutrition science and
medicine serving as examples. For researchers in nutrition science,
harnessing the Maillard reaction has allowed for control of food flavor, food
aroma, food coloring, and food texture (9 - 10). For researchers in clinical
medicine exploring the Maillard reaction has meant gaining a deeper insight
into the biochemistry of diabetes and its chronic complications including
renal failure, cataract formation and atherosclerosis (11 - 13).
Studies in our laboratory and those of others have shown that AGEs can
form both in vitro and in vivo, and that besides proteins can involve other
free amino containing molecules such as DNA, RNA, lipids, amino acids
and amino sugars (14 - 17). The objectives of this study were three fold: first,
to determine if melamine can be glycated by by D-galactose, D-glucose and
lactose, three sugars that are present in milk; second, to compare the
glycation levels of melamine with D-galactose, D-glucose and lactose; third,
to determine if melamine can nonenzymatically react with methylglyoxal,
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glyoxal and DL-glyceraldehyde, three highly reactive metabolic products of
D-galactose, D-glucose and lactose (15; 18 - 21).
In this report, we show that melamine is susceptible to glycation by
D-galactose and demonstrate the ability of melamine to form AGEs. We
also describe the nonenzymatic glycation of melamine with methylglyoxal,
glyoxal, and DL-glyceraldehyde, the three more reactive metabolites of milk
sugars. Emphasis is also placed on the characterization of the AGEs of
melamine by HPLC, UV, fluorescence and mass spectrometry.

2 Materials and methods
2.1 Chemicals and supplies
Analytical grade D-galactose, D-glucose, lactose, glyoxal, methylglyoxal,
DL-glyceraldehyde and melamine were purchased from Sigma Chemical
Co. (St. Louis, MO). Disposable UV-transparent cuvettes (12.5 mm X12.5
mm X 36 mm) and HPLC analytical grade solvents were obtained from
Thermo Fisher Scientific (Rockford, IL). Reverse phase HPLC columns
containing C8 silica resins were obtained from Agilent Technologies
(Chelmsford, MA) with all other HPLC supplies from Phenomenex
(Torrance, CA).

2.2 Preparation of reaction mixtures
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2.2.1 Reaction of lactose, D-glucose and D-galactose (milk sugars) with
melamine: Stock solutions of melamine (5 mM) and sugar (300 mM)
were prepared in 0.1 M phosphate buffer, pH 6.7. Final incubation
mixtures included variable amounts of melamine (0.2, 1, or 2.5 mM)
with a set concentration of D-glucose, D-galactose or lactose (150
mM). Blanks included melamine alone (0.2, 1 or 2.5 mM) or sugar
alone (lactose, D-glucose or D-galactose) each at a final
concentration of 150 mM. Freshly mixed sugars with melamine
served as the control solutions. All reaction mixtures and blanks were
incubated in the dark in a shaking water bath for 2 hours at variable
temperatures (40 °C, 50 °C, 60 °C, 70 °C, 80 °C and 90 °C). After
incubation, samples were placed at -20 °C until analyzed.
2.2.2 Reaction of methylglyoxal, glyoxal and DL-glyceraldehyde with
melamine: Unless otherwise indicated, all reactions were conducted
in 0.2 M phosphate buffer, pH 7.2, containing 0.02% sodium azide.
Stock solutions of melamine (5 mM), methyglyoxal (40 mM), glyoxal
(40 mM) and DL-glyceraldehyde (40 mM) were prepared by
separately dissolving each in the 0.2 M phosphate buffer. Final
incubation mixtures included variable amounts of methylglyoxal,
glyoxal or DL-glyceraldehyde (5 or 20 mM) with different
concentrations of melamine (0.2, 1, or 2.5 mM). Blank solutions
included methylglyoxal, glyoxal or glyceraldehyde alone (5 mM or 20
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mM), or melamine alone (0.2 mM, 1 mM or 2.5 mM). Controls
included non-incubated freshly mixed solutions of each aldehyde
(methylglyoxal, glyoxal or DL-glyceraldehyde) with melamine. All
reaction mixtures and blank solutions were incubated in the dark at
37 °C in a shaking water bath for 30 days. After incubation, samples
were placed at -20 °C until analyzed.

2.3 UV and fluorescence spectroscopy
UV readings were obtained at a wavelength of 240 nm with an UltroSpec
2100

instrument

(Biochrom

Ltd,

Cambridge,

UK).

Fluorescence

measurements were made at respective excitation and emission
wavelengths of 260 nm and 380 nm using a Spectra Max M2 spectrometer
(Molecular Devices, Sunnyvale, CA). All readings were obtained in
thermostatically controlled cuvettes that were maintained at 25±1 °C. The
above excitation and emission wavelengths were determined optimal for
detecting melamine AGEs.

2.4 High-performance liquid chromatography
Each HPLC run was performed in triplicate using a Hitachi system (San
Jose, CA, USA) equipped with a low-pressure gradient pump (L-2130), a
four-channel degasser, a sequential auto sampler (L-2200), and a high
sensitivity diode-array detector (190–800 nm) (L-2455). AGE species were
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separated on a C8 reverse phase HPLC column (5 μm×4.6 mm×150 mm)
and monitored at 240 nm. Mobile phase consisted of a 92% solution of 10
mM citrate heptane sulfonate buffer, pH 3.0 and 8% acetonitrile. An
isocratic condition was applied for 15 min at a constant flow rate of 1.00 ml
min-1. Prior to HPLC analysis, all solvents were filtered with a 0.45 μm
membrane (Millipore, Billerica, MA, USA), degassed for 15 min, and
centrifuged.

2.5 Mass spectrometry
Mass spectrometry studies were performed on a ThermoFinnigan LCQ
mass spectrometer (ThermoScientific, Waltham, MA) equipped with an
electrospray ionization source and a quadrupole ion trap mass analyzer.
Samples were diluted into a solvent consisting of 50/50 (v/v) 0.1% acetic
acid in water/acetonitrile and directly infused into the electrospray source
using a capillary syringe pump at a flow rate of 3 μL min-1. Nitrogen was
used as the sheath gas (setting at 60), and ultrapure helium was used as
the collision gas. The ion spray voltage was set as 4.5 kV and the capillary
temperature was 210 °C. The mass spectrometer was set to function in the
positive ion mode with parameters optimized during direct infusion of
caffeine standards with solvent. Samples were analyzed by MS and tandem
mass spectrometry (CID fragmentation with Helium) favoring isolation and
fragmentation of singly charged ions. The ESI/MS system was operated
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with the Xcalibur software (version 2.0, ThermoFinnigan), with the same
software used also for data analysis.

3 Results
Figure 2a and 2b show the time course of melamine’s glycation with
D-glucose, D-galactose and D-lactose under temperature and pH conditions
employed in the manufacture of powdered milk products. The amounts of
D-glucose, D-galactose and lactose were adjusted to actual concentrations
of the sugars in unprocessed milk and lactose free milk formulas [22]. At pH
6.7 and 80 °C for 120 min, D-glucose and D-lactose were found to be poor
glycators of melamine yielding UV and fluorescence spectral profiles that
were nearly superimposable. Under equivalent incubation conditions,
mixtures of D-galactose and melamine yielded higher fluorescence readings
demonstrating that relative to D-glucose and D-lactose, D-galactose was a
more effective glycator of melamine. As expected, the blank solutions and
controls yielded no changes in their fluorescence, confirming that for
glycation to occur, both sugar and melamine had to be in the same reaction
mixture and incubated over time.
The pronounced reactivity of D-galactose relative to D-glucose may be
explained by the enhanced general instability of the hemiacetal ring of
D-galactose, which in solution renders the molecule more prone to an
open-chain configuration [23, 24]. Thus, with a higher percentage of the
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sugar existing in an open ring structure than D-glucose, D-galactose
becomes more vulnerable to nucleophilic attack by the amino groups on
melamine [23, 24]. This phenomenon may also explain galactose’s higher
reactivity than D-lactose since as a disaccharide, lactose contains
D-glucose at it reducing end.
Figures 3A, 3B and 3C display the respective HPLC elution profiles of
mixtures of melamine incubated with D-galactose, D-glucose and lactose at
80 °C for 1 hour. Figure 3D shows the HPLC elution profiles of solutions
containing melamine alone (blank), and melamine freshly added to
D-galactose, D-glucose or D-lactose (controls). Melamine alone eluted as
one prominent peak with a retention time (Rt) of 7.40 min. Each of the
control mixtures yielded an elution profile identical to the blank, showing one
peak coincident to where melamine eluted (Rt 7.40 min).
The HPLC chromatograms in figures 3A to 3D revealed two important
things: 1) that glycation was a time dependent process requiring the
presence of both melamine and sugar, and 2) that D-galactose was a more
potent glycator of melamine than D-glucose and D-lactose, a finding
consistent with the fluorescence data in figure 2. Incubation mixtures of
D-galactose with melamine yielded three distinct AGE products by HPLC.
Of the bands corresponding to the AGE products, one eluted with a
retention time of 3.85 min, one at 4.49 min and one at 5.08 min (figure 3A).
A fourth band appearing at a retention time of 7.40 min corresponded to the
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fraction of melamine that did not condense with D-galactose. Integration of
the band areas revealed that with D-galactose as the glycating sugar 32.1%
of melamine was nonenzymatically modified; i.e., in contrast to 12.3% with
D-glucose and 6.3% with D-lactose. Other results revealed that reducing the
incubation temperatures, reduced the extent glycation of melamine and the
number of AGEs of melamine in the reaction mixtures. Figures 4A, 4B and
4C exemplify this behavior with D-galactose as the model glycating agent.
Tables I displays the changes in UV absorption readings of incubation
mixtures of melamine with methylglyoxal, glyoxal and DL-glyceraldehyde
(hereon referred to as “aldehydes”) at 37 °C covering different time intervals.
Increasing incubation time enhanced the AGE formation of melamine with
the highest levels of glycation achieved when aldehyde concentrations were
adjusted to 20 mM. A close scrutiny of the table confirmed the earlier
observations that the extent glycation of melamine was a time dependent
process relatable to the chemistry and concentration of the aldehydes in the
incubation mixtures. Increases in the aldehyde concentrations prompted
AGE formation, with methylglyoxal yielding the highest UV absorbing
products followed by glyoxal then DL-glyceraldehyde (figures 5a and 5b).
Increases in melamine concentration in the presence of set amounts of the
various aldehydes also promoted AGE formation, demonstrating that the
rate of glycation reaction was dependent on both the concentrations of
melamine and the various aldehydes (data not shown). Using variable
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amounts of melamine in the incubation mixtures had no effect on the
intensity order of the glycated compounds that were formed with
methylglyoxal and DL-glyceraldehyde, once again, producing AGEs with the
highest and lowest UV intensities, respectively.
Table II and figures 6A, B and C show the HPLC retention times of the
various

AGEs

of

melamine

with

methylglyoxal,

glyoxal

and

DL-glyceraldehyde at 37 °C over 30 days. Included in Table II is also the
number of AGE products and their percent amount relative to the total AGEs
in each incubation mixture over time. The band eluting at retention time 7.4
min was assigned to nonglycated melamine; an observation based on the
HPLC elution profiles of both the blank and control solutions (figure 6D).
Analysis of the data in Table II showed that with methylglyoxal there were
more AGE products formed than with glyoxal and DL-glyceraldehyde, with
DL-glyceraldehyde yielding the lowest number of AGEs. A further
evaluation of the results in Table II revealed that glyoxal was the most active
glycator of melamine followed by methyglyoxal then DL-glyceraldehyde
(figure 7).
Figures 8 shows the mass spectral profiles of 2.5 mM melamine incubated
with 20 mM methylglyoxal at 37 °C for 30 days. Mass spectral analysis of
melamine alone yielded one primary peak located at m/z 127 (data not
shown). In reaction tubes containing melamine and methylglyoxal, the main
product ions were at m/z 199, 271, and 343. The product with m/z 199
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corresponded to the addition of one methylglyoxal monomer (Δ m/z 72) to
melamine, whereas those with m/z 271 and 343 corresponded to the
condensation of two and three monomers.
Figure 9a-c show the CID mass spectrum for methylglyoxal’s primary
product ion at m/z 199 (figure 9a), 271(figure 9b) and 343 (figure 9b) with
the main fragmentation pattern revealing a loss in water (-18 Da) and a loss
in CO (-28 Da). The absence of a peak at m/z 155 indicated that no
carboxylic acid functional group was present. This conclusion was further
supported by the absence of a peak at m/z 197 after repeated analysis of
the sample in the negative ion mode. The product ion at m/z 199 appears to
contain a hemiaminal structure without loss of water forming a Schiff base at
pH 7.2.
For the reaction with 20 mM glyoxal (figure 10), a prominent peak at m/z
185 was observed. This ion corresponded to the addition of one glyoxal
monomer (Δ m/z 58) to melamine. Figure 11a shows the CID mass
spectrum for glyoxal product ion at m/z 185 with the main fragmentation
pattern, again, showing a loss in water (-18 Da), and a loss in CO (-28 Da).
This suggests that the reaction of melamine with glyoxal was similar to that
of methylglyoxal in forming a hemiaminal structure.
In contrast to glyoxal and methylglyoxal, glyceraldehyde condensed with
melamine through a Schiff base/Amadori reaction, forming a product ion at
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m/z 199 (figure 12). The mass spectrometric profile of D-galactose with
melamine was more difficult to interpret (figure 14); however, the product
ion at m/z 289 suggested the occurrence of Schiff base formation between
the anomeric carbon of D-galactose with one of the amino groups of
melamine. This result was confirmed by CID fragmentation of the product
ion at 289 (figure 15a). The additional ions indicated that more than one
D-galactose monomer could have condensed with melamine with the latter
then rearranging to yield multiple products.
Figures 16A thru 10D display the proposed structures consistent with the
mass spectral data for the primary products formed in incubation mixtures
containing melamine with methylglyoxal, glyoxal, DL-glyceraldehyde and
D-galactose. A detailed analysis of the predominant product ions generated
from the reaction of melamine with methylglyoxal (figure 8) leads to the
postulated mechanism pathway for the formation of AGEs seen in Figure 17.
It should be noted that a portion of the signal for ion at m/z 181 in the mass
spectrum (figure 8) could be arising from the dehydration of the ion at m/z
199 in the electrospray source.
Other findings revealed that increases in pH promoted melamine AGEs with
D-galactose and methylglyoxal (figure 18). This effect of pH on the glycation
of melamine was not surprising since increases in pH have been shown to
promote Schiff base formation (15 - 16).
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4 Discussion
Melamine is a chemical that has been employed in the manufacture of
adhesives, laminates, plastics, floor tiles, kitchenware, and commercial
filters. Yet, it has been also used as an additive to artificially boost a food’s
protein content, creating a lucrative market for edibles believed to be of
nutritious value. The deliberate adulteration of foods with melamine would
not have surfaced, if it wasn’t for the recent events of 2007 and 2008. In
2007, there was an outbreak of acute renal failure in cats and dogs in the
United States that resulted in the death of hundreds of animals across the
country (25). Investigations into the etiology of the outbreak traced the
problem to gluten, an ingredient in pet foods exported from China found
contaminated with ‘scrap melamine’ (26 - 27). ‘Scrap melamine’ is a
byproduct of melamine industry that in addition to melamine contains
variable amounts of cyanuric acid including different oxytriazines (28).
Melamine alone has been shown to cause no or little toxicity in animals (29 30); however, when combined with cyanuric acid, the two chemicals can
trigger the formation of kidney stones which ultimately leads to renal failure
(29 - 31).
In 2008, the melamine crisis expanded from a pet problem to a human
problem when ‘scrap melamine’ was discovered in infant’s formulas,
powdered milk and other dairy products; blamed for the sickening of
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countless children and the death of at least several infants in China (1; 3;
32). The melamine contamination was also found in non-dairy food products
made in China such as candies, egg products and non-dairy creamers,
some of which have been exported to other countries (29; 31 - 32). The
deliberate adulteration of edibles with melamine caused an unprecedented
hysteria throughout China forcing Beijing to adopt stricter food safety
regulations and to step up inspection of its dairy industry. The crisis of 2008
also triggered urgency for new standards to be set for tolerable daily levels
of melamine. For instance, in the US, the FDA has now set the limit from
0.63mg to 0.063 mg per kg of body mass, whereas in Europe the limit now
stands at 0.2 mg (2; 29; 31).
Melamine is rich in nitrogen and contains three amino groups which form
part of its hexagonal structure (figure1). These amino groups make
melamine a target for glycation as we have shown here in this study. Our
work with melamine revealed four important findings. First, it demonstrated
that melamine can non-enzymatically react with sugars most abundant in
milk and their metabolites. Second, it revealed that glycated products of
melamine can with time form AGEs that could be readily resolvable by
HPLC. Third, the observation was made that not all sugars and aldoses
reacted at the same rate and extent with melamine and that increased
temperatures

and

pH

accelerated

AGE

formation.

Lastly,

mass

spectrometric data revealed that glycation of melamine occurred via the
60

Amadori pathway yielding different AGE products with methylglyoxal,
glyoxal, DL-glyceraldehyde and D-galactose.
At present, there is little information on the long term toxicity of melamine
and human consumption, and there is practically no data on the toxicity of
glycated melamine in vivo. The high reactivity of melamine with milk sugar
metabolites suggests that the immediate and long term toxicity of melamine
may not only be related to its interactions with cyanuric acid, but may be
caused also by its Maillard products.
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Figure 1. Chemical structure of melamine (1,3,5-triazine-2,4,6-triamine).
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Figure 2a. Time course UV spectral profiles of reaction mixtures containing
150 mM milk sugar (D-galactose, D-glucose or) lactose with 1 mM of
melamine at 80 °C for 2 hours. Blank solutions were incubated under
identical conditions as above and included either sugar (150 mM) alone, or
melamine alone (1 mM). All points represent the average of triplicate
measurements. Every reading was compared with the highest reading set at
100%. Excitation and emission wavelengths were set at 260 nm and 380
nm, respectively.
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Figure 2b. Time course fluorescence spectral profiles of reaction mixture
containing 150 mM milk sugar (D-galactose, D-glucose or lactose) with
1mM melamine at 80 °C for 2 hours. Blank solutions were incubated under
identical conditions as above and included either sugar (150 mM) alone, or
melamine alone (1 mM). All points represent the average of triplicate
measurements. Every reading was compared with the highest reading set at
100%. Excitation and emission wavelengths were set at 260 nm and 380
nm, respectively.
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Figure 3. HPLC elution profile of melamine (1 mM) after 1 hour of incubation
at 80 °C with 150 mM D-galactose (A), D-glucose (B) and lactose (C).
Control reaction mixtures contained freshly mixed solutions of sugar with
melamine (D). Repeat chromatographic studies by HPLC revealed no
significant difference in the elution profiles and the retention times of the
different AGEs.
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Figure 4. HPLC elution profile of melamine with D-galactose in phosphate
buffer, pH 6.7 after the incubation of the two reactants for 1 hour at 90 °C
(A), 70 °C (B), and 40 °C (C). Repeat chromatographic studies by HPLC
revealed no significant differences in the elution profiles and the retention
times of the different AGEs in the above reaction mixtures.
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Figure 5 a and 5 b show the UV absorbance profiles of incubation mixtures
containing varied amounts of methylglyoxal, glyoxal and DL-glyceraldehyde
(5 mM in a and 20 mM in b) with set concentrations of melamine (2.5 mM) in
phosphate buffer, pH 7.2 at 37 °C for 30 days. Blank solutions were
incubated as above with either aldehyde alone (5 mM and 20 mM), or
melamine alone (2.5 mM). All UV readings were subtracted from the blank
readings.
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Figure 6. HPLC elution profiles of melamine (2.5 mM) with methylglyoxal
(20 mM) [A], glyoxal (20 mM) [B] and DL-glyceraldehyde (20 mM) [C] after
30 days incubation at 37 °C. Figure 6D shows HPLC elution profile of
melamine alone (2.5 mM) or melamine freshly incubated with aldehydes (20

74

mM each). All separations were performed on C8 reverse phase HPLC
column (5 μm×4.6 mm×150 mm) as described previously. Repeat
chromatographic studies by HPLC revealed no significant differences in the
elution profiles and the retention times of the AGE peaks.
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Figure

7. The order of

reactivity of

methylglyoxal, glyoxal and

DL-glyceraldehyde with melamine. Glyoxal was the most reactive glycator
of melamine followed by methylglyoxal then DL-glyceraldehyde. The
percentages of nonglycated melamine were calculated on the basis of the
ratio of HPLC band areas of nonglycated melamine to total band areas in
each chromatograph. All values in the figure are the average of triplicate
measurements. The variation of each set of triplicate readings is less than
1%.
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Figure 8. Mass spectral analysis of solutions of melamine [2.5 mM]
incubated with methylglyoxal [20 mM] (A) at 37 °C for 30 days.
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Figure 9a. CID mass spectra of mass spectrum profile in figure 8 recorded
on the (M+H)+ ion at m/z 199.

Figure 9b. CID mass spectra of mass spectrum profile in figure 8 recorded
on the (M+H)+ ion at m/z 271
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Figure 9c. CID mass spectra of mass spectrum profile in figure 8 recorded
on the (M+H)+ ion at m/z 343.
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Figure 10. Mass spectral analysis of solutions of melamine [2.5 mM]
incubated with glyoxal [20 mM] at 37 °C for 30 days.
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Figure 11a. CID mass spectra of mass spectrum profile in figure 10
recorded on the (M+H)+ ion at m/z 185.

Figure 11b. CID mass spectra of mass spectrum profile in figure 10
recorded on the (M+H)+ ion at m/z 244.
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Figure 11c. CID mass spectra of mass spectrum profile in figure 10
recorded on the (M+H)+ ion at m/z 261.

Figure 11d. CID mass spectra of mass spectrum profile in figure 10
recorded on the (M+H)+ ion at m/z 276.
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Figure 12. Mass spectral analysis of solutions of melamine [2.5 mM]
incubated with DL-glyceraldehyde [20 mM] (C) at 37 °C for 30 days.
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Figure 13a. CID mass spectra of the (M+H)+ ion for DL-glyceraldehyde
melamine product at m/z 199.

Figure 13b. CID mass spectra of the (M+H)+ ion for DL-glyceraldehyde
melamine product at m/z 271.
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Figure 13c. CID mass spectra of the (M+H)+ ion for DL-glyceraldehyde
melamine product at m/z 341.
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Figure 14. Mass spectral analysis of solutions of 2.5 mM melamine with 150
mM D-galactose at 80 °C incubated for 1 hour.
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Figure 15a. CID mass spectra of the (M+H)+ ion for D-galactose melamine
product at m/z 289.

Figure 15b. CID mass spectra of the (M+H)+ ion for D-galactose melamine
product at m/z 365.
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Figure 15c. CID mass spectra of the (M+H)+ ion for D-galactose melamine
product at m/z 473.
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Figure 16. Elucidation of structures consistent with mass spectrometric data
for primary products formed in incubation mixtures containing melamine
with methyglyoxal (A), glyoxal (B), DL-glyceraldehyde (C), and D-galactose
(D).
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Figure 17. Postulated pathway for the formation of melamine AGEs with
methylglyoxal.
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Figure 18. UV absorbance profiles of incubation mixtures of melamine (2.5
mM) with set concentration of methylglyoxal (20 mM) in phosphate buffer
under pH 6.0, 6.5, 7.0, 7.5, 8.0 at 37 °C for 48 h (A), or with set
concentration of D-galactose (150 mM) in phosphate buffer under pH 6.0,
6.5, 7.0, 7.5, 8.0 at 80 °C for 2 h (B). All readings were compared with the
highest reading, which was set at 100%. All points represent the average of
triplicate measurements, and every reading was found to be within 5% of its
counterpart triplicate.
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Table I
UV readings of incubation mixtures containing melamine (2.5 mM) and
different aldehydes (5 mM and 20 mM)
5 mM
Methylglyoxal

Actual UV
Reading

20 mM
Actual UV

% Relative Reading

Reading

%Relative Reading

0d

0.000±0.000

0.000

0.000±0.000

0.000

1d

0.075±0.002

0.336

0.271±0.003

0.321

0.080±0.001

0.359

0.290±0.003

0.344

1.000

†

1.000

2d
30 d

†

0.223±0.002

0.844±0.002

5 mM
Glyoxal

Actual UV
Reading

20 mM

% Relative Reading

Actual UV

% Relative

Reading

Reading

0d

0.000±0.000

0.000

0.000±0.000

0.000

1d

0.046±0.001

0.206

0.173±0.003

0.205

2d

0.051±0.003

0.229

0.184±0.003

0.218

30 d

0.116±0.001

0.520

0.366±0.004

0.434

5 mM
DL-Glyceraldehyde

Actual UV
Reading

20 mM

% Relative Reading

Actual UV
Reading

% Relative Reading

0d

0.000±0.000

0.000

0.000±0.000

0.000

1d

0.022±0.002

0.099

0.025±0.004

0.030

2d

0.026±0.001

0.117

0.031±0.002

0.037

30 d

0.080±0.002

0.359

0.302±0.003

0.342

Reaction mixtures included methylglyoxal, glyoxal and DL-glyceraldehyde (5 mM
or 20 mM) with melamine (2.5 mM) in phosphate buffer, pH 7.2 at 37 °C for 30
days. Blank solutions were incubated as above with either individual aldehydes
alone, or melamine alone. All readings were subtracted from the readings of the
blank solutions. % Relative readings were calculated based on the highest UV
values obtained within each set of reaction mixtures (5 mM or 20 mM aldehyde)
evaluated
† denotes the highest UV readings in each set of incubation mixtures.
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Table II
Peak Retention Times and Percentages of AGE Band Areas Resulting from
the Separation of Incubation Mixtures Containing Methylglyoxal, Glyoxal and
DL-Glyceraldehyde with Melamine by HPLC
* % Band Area of

Time

Nonglycated

(Day)

Melamine (Rt=7.4
1

2

3

4

5

6

7

8

9

10

min)

MG

0

100.0%

2

74.9%

10

54.4%

30

39.9%

0

100.0%

2

61.6%

10

29.3%

30

3.5%

0

100.0%

2

91.9%

10

75.9%

30

54.5%

Gly

GA

* Denotes the fractions of nonglycated melamine eluted at retention time of
7.4 min.

93

Manuscript 3
Prepared for Analytical Biochemistry
Anticipated submission date: January, 2013

Inhibitory Effect of Gold Nanoparticles on the Glycation of Bovine
Serum Albumin by D-Ribose
Weixi Liu 1, Menashi A. Cohenford 2, Leslie Frost 3, Champika Seneviratne 1,
Joel A. Dain 1*
1

Department of Chemistry, University of RI, Kingston, RI 02881
Department of Integrated Science and Technology, Marshall University, Huntington,
WV 25755
3
Department of Chemistry, Marshall University, Huntington, WV 25755
2

E-mail address: wliu@chm.uri.edu (Weixi Liu).
E-mail address: cohenford@marshall.edu (Menashi A. Cohenford).
E-mail address: frost@marshall.edu (Frost Leslie)
E-mail address: pseneviratne@chm.uri.edu (Champika Seneviratne)
*Corresponding author: Phone: + 1-401-874-5942; fax: + 1-401-874-5072
E-mail address: jdain@chm.uri.edu (Joel A. Dain).

94

Abstract:
The

formation

of

advanced

glycation

endproducts

(AGEs)

by

non-enzymatic glycation of protein with reducing sugar is a major
contributor to the pathology of diabetes, Alzheimer’s disease and
atherosclerosis. Previous study in our laboratory showed that 2 nm gold
nanoparticles (GNPs) exhibit an inhibition effect on the formation of AGEs
when serum albumin was glycated with DL-glyceraldehyde. The objective
of this study was to evaluate the rate and extent of AGE formation of
bovine serum albumin (BSA) in the presence of GNPs with varied sizes. A
combination of UV spectrometry, HPLC and circular dichroism showed
that only GNPs with size ranging from 2nm to 20nm inhibited the formation
of BSA AGEs. The inhibition effect of GNPs was correlated to the overall
surface area of nanoparticles in the solution. GNPs with higher surface
areas were found to be better inhibitors of glycation, whereas those with
low surface areas were less effective inhibitors. MALDI-TOF spectrum
showed that in the presence of GNPs, BSA was less prone to be glycated
by reducing sugar comparing to reaction mixtures absent of GNPs. The
inhibitory effect of GNPs on non-enzymatic glycation reactions may be
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due to the covalent bonding between gold atoms on the surface of GNP
and ε amino groups of L-lysine residue on protein. As GNP is highly
biocompatible and water soluble, an insight of its anti-glycation effect and
its inhibition mechanism on the formation of AGEs might lead to a novel
therapeutic application of GNP on reducing AGE related complications.

Key Words: gold nanoparticle; glycation; AGEs; BSA; D-ribose

1 Introduction
Glycation is a non-enzymatic reaction with reactants including a
reducing sugar and a free amino containing molecule such as protein, lipid or
nucleic acid. The reaction initiates with a nucleophilic attack of the free
amino group on biomolecule to the carbonyl group of a reducing sugar,
forming an unstable Schiff base structure. The Schiff base will then
rearrange to a more stable ketoamine known as Amadori product. Under
physiological condition, this Amadori product can undergo series of
irreversible chemical reactions including self-degradation and condensation
with other proteins, leading the formation of a heterogeneous group of
compounds referred to as advanced glycation endproducts (AGEs) [1, 2].
The graduate accumulation of AGEs in vivo has been implicated as a major
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contributor to various diabetic complications including renal failure, diabetic
atherosclerosis and cataract formation, as well as other health disorders,
such as Alzheimer’s disease (AD) [3-5]. Abnormal built up of AGEs under
hyperglycemia

condition

could

trigger

the

generation

of

harmful

inflammatory factors and reactive oxygen species, resulting in tissue
damage. Long lived protein which has a low clearance rate tends to form
crosslinking structures with certain type of AGEs and gradually lose its
function in vivo.
Since the non-enzymatic glycation of proteins is tightly related to the
pathology of long-term diseases, the inhibitors to prevent the formation of
AGEs have been extensively investigated over years [6-8]. The reactants
involved in the initial stage of glycation are a common target for
anti-glycation drug design [9, 10]. This class of inhibitors act as sugar
competitors by interacting with target glycation amino acid residues, most
commonly lysine and arginine, and prevent their further modification by
reducing sugars. Two notable potential anti-glycation agent fall into this class
include acetylating aspirin and aldehyde pyridoxal-5’-phosphate.
Previous study in our laboratory showed that 2 nm gold nanoparticles
(GNPs) exhibit an inhibitory effect on the formation of AGEs when Human
Serum Albumin (HSA) was glycated by DL-glyceraldehyde [11]. GNP
typically refers to gold colloid with a particle size ranging from one
nanometer to several hundred nanometers. Due to its unique optical
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property, very large surface-to volume ratio and easy modification, GNP has
been applied in a broad range of fields including biomedicine, bio-imaging,
material science and synthetic chemistry [12-14].
Proteins and amino acids are able to covalently bond to the gold atoms
on the surface of nanoparticle through Au-S or Au-NH2 bonds [15, 16]. The
binding of biomolecules to GNP can stabilize the particle from conjugation
and enhance its solubility in aqueous solution as well [17]. In the meanwhile,
free amino groups in proteins or peptides, some of which are the seeding
sites of GNP to these biomolecules, might also be reaction sites susceptible
to glycation by reducing sugar. This suggests that the specific covalent
bonding of GNP to these amino groups in protein might be able to protect
these sites from glycation. Furthermore, GNP could possibly bind to the
glycation intermediates of protein and prevent the formation of reactive
dicarbonyl compounds. By trapping these AGE precursors, GNP could
stabilize and fix the protein structure from further alteration and prevent the
formation of AGEs.
The objective of this study was to evaluate the rate and extent of BSA
glycation by D-ribose in the presence of spherical GNPs. A combination of
UV spectrometry, HPLC, circular dichroism and MALDI were used to
determine the formation of AGEs. This study emphasized also on the effect
of different nanoparticle sizes on GNP’s inhibitory efficiency. The correlation
between particle size, total particle surface area in solution and GNP’s
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anti-glycation ability was evaluated by two separate experiments designated
as experiment A and B. As GNP is highly biocompatible and water soluble,
an insight of its anti-glycation effect and its inhibition mechanism on the
formation of AGEs might lead to a novel therapeutic application of GNP on
reducing AGE related complications.

5 Materials and methods
5.1 Chemicals and supplies
Fatty acid free albumin from bovine serum (BSA) and analytical grade
D-ribose were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO,
USA). Citrate reduced colloidal solution of spherical gold nanoparticles with
variable sizes (2nm, 5nm and 20nm) were purchased form Ted Pella Inc.
(Redding, CA, USA). Disposable UV-transparent cuvettes (12.5 mm X12.5
mm X 36 mm) and HPLC analytical grade solvents were obtained from
Thermo Fisher Scientific (Rockford, IL, USA). ZipTip pipette tips with C 4
resin and 0.22 µm filter unit were purchased form EMD Millipore Co.
(Billerica, MA, USA). Unless otherwise indicated, all other reagents of
analytical grade were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO, USA).
5.2

Preparation of reaction mixtures

5.2.1 Stock solutions of BSA (105 mM) and D-ribose (100 mM) were
prepared in 0.1 M phosphate buffer, pH 7.2. Gold colloids with
different sizes of nanoparticles (2 nm, 5 nm, 20 nm, 50 nm, 100 nm
99

and 200 nm) were suspended in water and adjusted to a final Au
mass concentration of 0.01 mg/ml each. Blank solutions included 35
mg/ml BSA alone, 20 mM D-ribose alone and 35 mg/ml BSA with
different sizes of GNP without D-ribose. Controls included 35 mg/ml
BSA incubated with 20 mM D-ribose at the absence of GNP. The
concentration of BSA was adjusted to 35 mg/ml because this is the
reported

serum

albumin

concentration

physiologically.

The

concentration of D-ribose was adjusted to 20 mM representing the
blood sugar content under diabetic condition. D-ribose was chosen as
the model glycated agent due to its greater reactivity comparing to
D-glucose and its important role in several bio pathways related to
carbohydrates metabolism.
5.2.2 Experiment A: Reaction mixtures contained 35 mg/ml BSA and 20
mM D-ribose with different sizes of GNP (2 nm, 5 nm and 20 nm) at
set Au concentration of 0.005 mg/ml, resulting in different particle
number and total particle surface area in each solution (Table I). All
reaction mixtures and blanks were incubated in the dark at 37 °C in a
shaking water bath for 21 days. After incubation, samples were
placed at -20 °C until analyzed. Prior analysis, all samples were
ultra-centrifuged at 1X104 rpm for 30 min and the supernates were
further purified by ZipTip pipette with C4 resin.
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5.2.3 Experiment B: Reaction mixtures contained 35 mg/ml BSA and 20
mM D-ribose with different sizes of GNP (2 nm, 5 nm and 20 nm) at
different Au mass concentrations of 0.02 mg/ml, 0.01 mg/ml and
0.05mg/ml respectively. Such dilution resulted in an approximate
identical total nanoparticle surface area in each solution containing
different sizes of GNPs. All reaction mixtures and blanks were
incubated in the dark at 37 °C in a shaking water bath for 21 days.
After incubation, samples were placed at -20 °C until analyzed. Prior
analysis, all samples were ultra-centrifuged at 1X104 rpm for 30 min
and the supernates were further purified by ZipTip pipette with C4
resin.
5.3 UV and fluorescence spectroscopy
UV spectrum with wavelength ranging from 200 nm to 400 nm was
determined on an UltroSpec 2100 instrument (Biochrom Ltd, Cambridge,
UK). Fluorescence measurements were made at respective excitation and
emission wavelengths of 340 nm and 420 nm using a Spectra Max M2
spectrometer (Molecular Devices, Sunnyvale, CA, USA). All samples were
diluted 50 fold before analysis and all readings were obtained in
thermostatically controlled cuvettes that were maintained at 25±1 °C. The
above excitation and emission wavelengths were determined optimal for
detecting BSA AGEs.
5.4 Circular dichroism
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CD analysis were performed at a Jasco J-720 spectropolarimeter
(Tokyo, Japan) using a quartz cuvette of 1 mm path length. The instrument
was controlled by Jasco’s Spectra Manager software. Before analysis, the
concentration of BSA was adjusted to 0.5 mg/ml using 0.1 M phosphate
buffer, pH 7.2. Signals were obtained in the far-ultraviolet region
(190-250nm). A total of 10 consecutive scans with bandwidth of 1 nm, scan
speed of 20 nm/min and response time of 2 s were averaged. The spectrums
were then subtracted by corresponding blanks to eliminate any buffer effect.
5.5 High-performance liquid chromatography
Each HPLC run was performed in triplicate using a Hewlett Packard
1050 system (Waldbronn, Germany) equipped with a low-pressure gradient
pump, a four-channel degasser, a sequential auto sampler, a high sensitivity
diode-array detector (190–800 nm) and a programmable fluorescence
detector (HP 1046A). The HPLC system was operated with the ChemStation
System from Agilent Technologies (Santa Clara, CA, USA) with the same
software used also for data analysis. AGE species were separated on a
Shodex (New York, NY, USA) RSpak C18 reverse phase HPLC column (5
μm×4.6 mm×150 mm) with 415 Å pore size. Mobile phase A consisted of 0.1%
trifluoroacetic acid (TFA) and 1% acetonitrile (ACN) in water and mobile
phase B consisted of 0.1% TFA and 95% ACN in water. A linear gradient
from 20% to 60% of mobile phase B was applied in 25 minutes at a constant
flow rate of 1.0 ml/min. Prior to HPLC analysis, all solvents were degassed
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and sonicated for 15 min. All samples were filtered with a 0.22 μm
membrane, degassed and centrifuged.
5.6 Preparation and analysis of intact HSA by MALDI-TOF MS
All samples were purified with C4 ZipTips and analyzed on a Bruker
Autoflex MALDI–TOF (time-of-flight) mass spectrometer (Bruker Daltonics,
Billerica, MA, USA). Prior to analysis, the protein samples (0.6 μl) were
mixed with a 50% aqueous acetonitrile solution (0.6 μl) of saturated sinapinic
acid containing 0.05% trifluoroacetic acid (TFA) as matrix, spotted onto a
stainless steel sample plate, and allowed to air dry. Spectra were acquired in
linear TOF mode with a 550 ns delay in the m/z range from 20,000 to 80,000.
Each spectrum was the sum of 500 single laser shots randomized over 10
positions within the same spot (500/50). Analysis of data was performed
using FlexAnalysis and ClinProTools (Bruker Daltonics).

3. Results
Figure 1 displays the respective UV spectral profiles of reaction
mixtures in experiment A after 21 days incubation in dark at 37 °C. It should
be noted that spherical GNPs with particle diameter larger than 20 nm (50
nm, 100 nm and 200 nm) aggregated with BSA after two to three days
incubation, forming insoluble precipitants in phosphate buffer. Thus only 2
nm, 5 nm and 20 nm GNPs which retained their nanoparticle properties
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without aggregating with BSA during incubation were evaluated in the
following study.
Profiles in figure 1 from top to bottom are a) 35 mg/ml BSA incubated
with 20 mM D-ribose at the absence of GNP, b) 35 mg/ml BSA glycated by
20 mM D-ribose at the presence of 20 nm GNP, c) 35 mg/ml BSA glycated
by 20 mM D-ribose at the presence of 2 nm GNP, d) 35 mg/ml BSA glycated
by 20 mM D-ribose at the presence of 5 nm GNP and e) 35 mg/ml BSA
incubated in buffer alone. The UV spectrum scans ranged from 250 nm to
400 nm in each profile. Comparing to BSA blank, reaction mixture containing
BSA and D-ribose showed dramatic increase in UV absorbance intensity
after 21 days incubation, yielding a peak with the maximum absorbance at
around 280 nm (profile a). Aromatic rings are known as the primary reason
for the absorbance peak at 280 nm and the increased BSA UV intensity at
280 nm revealed the formation and accumulation of aromatic AGEs. As a
result the increase in UV absorbance intensity at 280 nm could be used to
evaluate the extent of BSA glycation. Comparing to reaction mixture
containing BSA and D-ribose alone, BSA glycated in the presence of GNPs
(profile b, c and d) showed significant reduction in UV intensity at 280 nm
after 21 days incubation.
Though the absorbance measurements at 280 nm in profiles b, c and d
all decreased noticeably comparing to control reaction in profile a, the extent
of the reduction in each solution varied. Among three incubation mixtures of
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different sizes of nanoparticles, reaction with 5 nm GNPs showed the lowest
UV absorbance yielding a value of 0.151 at wavelength of 280 nm. In
comparison, control group without the treatment of GNP had a much higher
UV intensity at 280 nm valued 0.384. Followed by 5 nm GNP solution,
sample with 2 nm GNP exhibited the second lowest UV reading (λ280=0.180)
while sample with 20 nm GNP showed the highest UV intensity among the
three GNP containing mixtures (λ280=0.269). Previous study in our lab
demonstrated that increase in nanoparticle numbers in reaction solution was
directly correlated to its inhibitory efficiency against glycation, probably due
to the increased available binding area on the surface of GNP, which could
mask protein’s glycation sites. Adjusting Au mass concentration in profile b,
c and d to the same mass value of 0.05 mg/ml resulted in a different particle
number and total particle surface area in each solution. The value of total
particle surface area in unit volume (ml) was obtained by multiplying the
particle number in one unit volume (ml) with the single particle surface area
(nm2). According to table I, 5 nm GNP solution had the highest total particle
surface area in solution, followed by 2 nm GNP and then 20 nm. Interestingly,
this sequence corresponded to the order of their anti-glycation efficiency that
5 nm GNP showed the most reduction on the formation of AGEs while 20 nm
the least.
To further evaluate the correlation between nanoparticle size, total
particle surface area in solution and GNP’s anti-glycation ability, we
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conducted experiment B. In this separate study, we used the same blank
and control samples as experiment A, while adjusted the Au mass
concentration to 0.02 mg/ml, 0.01 mg/ml and 0.05 mg/ml for 2 nm GNP, 5 nm
GNP and 20 nm GNP solutions respectively, resulting in a same particle
surface area in all three GNP solutions. Figure 2 displays the UV absorbance
spectrums of reaction mixtures in experiment B and profiles from top to
bottom are: a) 35 mg/ml BSA incubated with 20 mM D-ribose at the absence
of GNP, b) 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 20
nm GNP, c) 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 5
nm GNP, d) 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 2
nm GNP and e) 35 mg/ml BSA incubated in buffer alone. BSA glycated by
D-ribose without the treatment of GNPs again yielded the highest UV
intensity while BSA blank showed the lowest. However, 2 nm GNP and 5 nm
GNP revealed a less inhibitory effect against glycation comparing to GNP
solutions in experiment A, yielding UV spectral profiles that were nearly
superimposable to that of 20 nm GNP. This suggested that all three GNP
samples which had the same total nanoparticle surface areas exhibited
similar ant-glycation abilities, regardless of the difference in their particle
sizes and Au mass concentrations.
Advanced glycation of BSA not only produces aromatic AGEs that can
be detected by UV absorbance, but also alters proteins secondary structure
whose change can be monitored by circular dichroism in the far-UV spectral
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region (190-250 nm). The secondary structure of BSA is composed of about
67% α-helix structure, so BSA conformation change was determine by
monitoring the loss of α-helix structure in each sample. Figure 3 shows CD
spectrum profiles for experiment A in the far-UV spectral region and figure 4
shows the CD data for samples in experiment B. The CD spectrum for intact
BSA without the treatment of reducing sugar and GNPs featured a
well-defined helical pattern, with characteristic double dip at 205 nm and 222
nm. BSA and D-ribose mixture incubated for 21 days showed drastic
reduction of the featured helical pattern, indicating that BSA has lost α-helix
structures during glycation due to the formation of AGEs and the consequent
protein conformation change.
In experiment A (figure 3), profile b, c and d are designated to BSA
glycated by D-ribose in the presence of 20 nm, 2 nm and 5 nm GNP solution
respectively. Similar to earlier observations from UV spectrum scan, reaction
mixture with 5 nm GNP retained most of the α-helical content of BSA,
producing a spectrum profile most similar to the profile of natural BSA which
has not been glycated by reducing sugar. BSA treated by 2 nm and 20 nm
GNPs also revealed decreases in the loss of secondary structure comparing
to control BSA which was glycated without GNP. CD spectrums for samples
in experiment A revealed that reaction mixture with 5 nm retained the most
helical structure followed by 2 nm sample then 20 nm. In contrast, CD
profiles for experiment B seen in figure 4 showed that all three sizes of
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nanoparticle exhibited similar anti-glycation ability, producing CD spectrum
almost superimposable to each other.
Figure 5 and figure 6 display the respective HPLC elution profiles of
reaction mixtures in experiment A incubated at 37 °C for 21 days. Both UV
and fluorescence signals were monitored in the HPLC profile. Profile 5a
shows the HPLC-UV elution data of solutions containing BSA alone (blank).
BSA alone eluted as one prominent peak with a retention time (R t) of 15.79
min. BSA glycated by D-ribose without the treatment of GNPs (profile 5b)
yielded three AGE products by HPLC labeled as peak 1, 2 and 4. Of the
bands corresponding to the AGE products, peak 1 and 2 were not well
separated and eluted with a retention time of 2.25 min while peak three
eluted at 5.21 min. Integration of the band areas (data shown in table II)
revealed that without the treatment of GNPs, glycated BSA produced three
AGEs adducts with the first two yielding a total peak area of 258.62 and the
third of 12.39 respectively. In contrast, profiles of BSA glycated in the
presence of GNPs (5c, 5d and 5e) revealed a disappearance of peak 4,
indicating that less AGE species was formed in the presence of GNPs.
Moreover, the peak areas of peak 1 and 2 in profiles 5c, 5d and 5e were
noticeable reduced comparing to profile b, yielding a total AGE peak
intensity of 88.78, 82.10 and 87.23 respectively. Peak 3 in profile b, c d and e
indicated BSA with sugar addicts, yielding a broad HPLC band comparing to
that of native BSA. The peak area of this bank also demonstrated the extent

108

of glycation since BSA with more sugar addicts would produce a broader
band resulting in an increase in peak intensity. BSA glycated by D-ribose
without GNP, again, yield a band with the highest peak area of 316.67
indicating the production of glycated BSA with most sugar addicts. BSA
incubated with different sizes of GNPs all revealed a decrease in the peak
area, and 5 nm GNP exhibited the most reduction in BSA glycation with peak
intensity of 138.39, followed by 2 nm GNP (peak area= 151.95) and 5 nm
GNP (peak area= 173.65).
To determine the number of sugar addicts on protein forming by
glycation, we used MALDI-TOF to compare the mass shift of glycated BSA
with native BSA. Figure 7 to 11 are MALDI spectrum of reaction mixtures in
experiment A: native BSA (fig. 7), BSA incubated with D-ribose (fig. 8), BSA
and D-ribose mixture with 2 nm GNP (fig. 9), BSA and D-ribose mixture with
5 nm GNP (fig. 10), BSA and D-ribose mixture with 20 nm GNP (fig. 11). In
table III we summarized the peak m/z value in each MALDI profile and the
mass shift comparing to native BSA. Since the increase in m/z value was
mainly due to the addict of D-ribose molecules to the protein, the
approximate number of D-ribose adducts on glycated BSA in each
incubation mixture can be also calculated based on the shift in m/z value
(shown in table III). A greater number of sugar addicts on protein revealed a
higher extent of glycation, resulting in a more rapid and an enhanced
formation of AGEs. A close scrutiny of the table confirmed the earlier
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observations that the extent glycation of BSA was reduced by adding GNPs
into the solution. Mixture containing BSA and D-ribose alone showed the
highest shift in protein m/z value and 80 sugar molecules were estimated to
bond with native protein after 21 days incubation. The number of sugar
addicts was reduced considerably in reaction mixtures containing BSA and
D-ribose with 2 nm, 5 nm or 20 nm GNPs. 5 nm GNP solution which
exhibited the highest total nanoparticle surface area yielded the least shift in
m/z value, followed by 2 nm GNPs and then 20 nm. This order, again
corresponded to the order of total nanoparticle surface areas in each
solution (5nm>2nm>20nm), confirming that GNP’s anti-glycation ability is
directly correlated to the total nanoparticle surface area in each solution.
GNP solution with enhanced total surface area exhibited a higher inhibitory
effect against the formation of AGEs. This anti-glycation property of AGEs
was reduced by decreasing the nanoparticle numbers in solution which
resulted in a decrease of total particle surface area.
4. Discussion
The non-enzymatic glycation of protein by reducing sugars causes the
irreversible formation of AGEs, a heterogeneous group of compounds
accumulating in vivo over times. The built up of AGEs has been implicated
to be related to the pathology of several long term diseases including
diabetes and AD. Thus the search for anti-glycation agents is an important
clinical issue since an increasing amount of AGE modified proteins have
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been detected during the development of such diseases. Unfortunately,
though several potential inhibitors against the formation of AGEs have been
discovered and proposed, no promising anti-glycation drug has been
applied clinically. Since glycation is a complicated process involving multiple
targets and bio-pathways, the invention of inhibitors against such biological
event is challenging. In this study, we evaluated the effect of gold
nanoparticles on the formation of AGEs using BSA glycated by D-ribose as
model reaction. The anti-glycation efficiency of GNPs with different particle
diameters ranging from 2 nm to 200 nm was also compared.
Our studies showed that spherical GNPs with particle diameter larger
than 20 nm (50 nm, 100 nm and 200 nm) aggregated with BSA after two to
three days incubation, forming insoluble precipitants in phosphate buffer.
However, 2 nm, 5 nm and 20 nm GNPs retained their nanoparticle properties
without aggregating with BSA during incubation. Moreover, BSA-ribose
reaction mixture treated with 2 nm, 5nm or 20 nm GNP all showed a reduced
glycation level comparing to BSA incubated with D-ribose alone. UV
spectrum revealed that under the treatment of GNPs, less aromatic AGEs
were formed during the incubation of BSA with D-ribose. This result was
confirmed by HPLC elution profiles that less AGE peaks and lower peak
intensities were detected in reaction mixtures containing GNPs. It was also
shown that GNP retained the secondary structure of BSA and prevented the
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conformational change of protein, a finding which was demonstrated by CD
spectrum.
The other important finding of this study was the correlation between
GNP’s anti-glycation efficiency and the total nanoparticle surface area in the
solution. GNP’s inhibitory effect against the formation of AGEs could be
enhanced by increasing the total GNP particle surface areas in solution. This
can be achieved by increasing the total nanoparticle concentration or
increasing the nanoparticle sizes. It should be noted that larger size GNP or
saturated GNP solution tends to conjugate with protein and precipitates out.
Thus it is important to keep the particle size and concentration within a range
which GNPs still retain their nanoparticle properties without aggregating with
protein during glycation. In our study, we found that 5 nm GNPs with an Au
mass concentration of 0.05 mg/ml exhibited the most anti-glycation ability
while stayed homogenously during the entire incubation process.
The mechanism of GNP’s inhibitory effect against the formation of
AGEs is still under investigation. We proposed that GNPs competitively bind
to the potent glycation sites on BSA, preventing their further modification by
glycation. There is a strong implication that amino acid residues are able to
covalently bond to the gold atoms on the surface of nanoparticle through
Au-S or Au-NH2 bonds. Such binding not only stabilizes nanoparticle from
conjugation, but also protects free amino groups such as lysine from
glycation. Furthermore, GNP could possibly bind to the glycation
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intermediates of protein and prevent the formation of reactive dicarbonyl
compounds.
In the specific case of our study, GNP with a higher surface area
exhibited better inhibitory ability against glycation, probably due to the
increase in available binding area on GNP surface to protein’s potential
glycation sites. As GNP is highly biocompatible and water soluble, an insight
of its anti-glycation effect and its inhibition mechanism on the formation of
AGEs might lead to a novel therapeutic application of GNP on reducing AGE
related complications.
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Figure 1. UV absorbance spectrum of reaction mixtures in experiment A.
Each group contained 35 mg/ml BSA and 20 mM D-ribose incubated with
and without different sizes of GNP (2 nm, 5 nm and 20 nm) at 37 °C for 21
days. The Au mass concentration was adjusted to 0.05 mg/ml in solutions
containing GNP resulting in different total nanoparticle surface area (refer to
table I). The spectrum is ranging from 250 nm to 400 nm with glycation
products absorbed most at 280 nm. All data points represent the averages of
three replicate measurements.
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Figure 2. UV absorbance spectrum of reaction mixtures in experiment B.
Each group contained 35 mg/ml BSA and 20 mM D-ribose incubated with or
without different sizes of GNP (2 nm, 5 nm and 20 nm) at 37 °C for 21 days.
The total nanoparticle surface area in each solution was adjusted to the
same value (refer to table I). The spectrum is ranging from 250 nm to 400 nm
with glycation products absorbed most at 280 nm. All data points represent
the averages of three replicate measurements.
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Figure 3. CD profiles of reaction mixtures in experiment A: (A) 35 mg/ml BSA
and 20 mM D-ribose without GNP, (B) 35 mg/ml BSA and 20 mM D-ribose
with 20 nm GNP, (C) 35 mg/ml BSA and 20 mM D-ribose with 2 nm GNP, (D)
35 mg/ml BSA and 20 mM D-ribose with 5 nm GNP and (E) 35 mg/ml BSA
alone at 37 °C for 21 days. BSA concentration was diluted to 0.5 mg/ml with
deionized water before analysis. Repeat scan revealed no significant
difference in the spectra.
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Figure 4. CD profiles of reaction mixtures in experiment B: (A) 35 mg/ml BSA
and 20 mM D-ribose without GNP, (B) 35 mg/ml BSA and 20 mM D-ribose
with 20 nm GNP, (C) 35 mg/ml BSA and 20 mM D-ribose with 5 nm GNP, (D)
35 mg/ml BSA and 20 mM D-ribose with 2 nm GNP and (E) 35 mg/ml BSA
alone at 37 °C for 21 days. BSA concentration was diluted to 0.5 mg/ml with
deionized water before analysis. Repeat scan revealed no significant
difference in the spectra.
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Peak 1 and 2

Peak 3

Peak 4

Figure 5. HPLC-UV elution profile for reactions in experiment A. 35 mg/ml
BSA alone served as blank solution (a). 35 mg/ml BSA incubated with 20
mM D-ribose without GNP served as control solution (b). Profiles for BSA
glycated at the presence of different sizes of GNP are shown in c (20 nm), d
(5 nm) and e (2 nm). All reaction mixtures were incubated in dark at 37 °C for
21 days.
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Peak 2
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Figure 6. HPLC-fluorescence elution profile for reaction mixtures in
experiment A. 35 mg/ml BSA alone served as blank solution (a). 35 mg/ml
BSA incubated with 20 mM D-ribose without GNP served as control solution
(b). Profiles for BSA glycated at the presence of different sizes of GNP are
shown in c (20 nm), d (5 nm) and e (2 nm). All reaction mixtures were
incubated in dark at 37 °C for 21 days.
.
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Figure 7. MALDI-TOF profile of reaction mixtures containing 35 mg/ml BSA
incubated in dark at 37 °C for 21 days. The spectrum peak indicates to
double charge intact BSA. The maximum peak m/z value was found at
33100.
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Figure 8. MALDI-TOF profile of reaction mixture in experiment A which
contained 35 mg/ml BSA glycated by 20 mM D-ribose in dark at 37 °C for
21 days. The spectrum peak indicates to double charge glycated BSA. The
maximum peak m/z value was found at 39100.
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Figure 9. MALDI-TOF profile of reaction mixture in experiment A which
contained 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 2
nm GNP with Au mass concentration of 0.05 mg/ml. The reaction took place
in dark at 37 °C for 21 days. The spectrum peak indicates to double charge
glycated BSA. The maximum peak m/z value was found at 37170.
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Figure 10. MALDI-TOF profile of reaction mixture in experiment A which
contained 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 5
nm GNP with Au mass concentration of 0.05 mg/ml. The reaction took place
in dark at 37 °C for 21 days. The spectrum peak indicates to double charge
glycated BSA. The maximum peak m/z value was found at 36980.
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Figure 11. MALDI-TOF profile of reaction mixture in experiment A which
contained 35 mg/ml BSA glycated by 20 mM D-ribose at the presence of 20
nm GNP with Au mass concentration of 0.05 mg/ml. The reaction took place
in dark at 37 °C for 21 days. The spectrum peak indicates to double charge
glycated BSA. The maximum peak m/z value was found at 37780.
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Tables:

Table I.
Particle Size and Surface Area of 2nm, 5nm, 20nm Gold Colloid Water
Solution in Experiment A and B
Particle Size
(nm)

A

B

Particle/ml

Au Mass

Single Particle

Total Particle

Concentration

Surface Area

Surface Area/ml

2

2

(mg/ml)

(nm )

(nm /ml)

2 nm

1.5 X 1014

0.05

50

7.54 X 1015

5 nm

5.0 X 1013

0.05

314

15.7 X 1015

20 nm

7.0 X 1011

0.05

5024

3.52 X 1015

2 nm

7.0 X 1013

0.02

50

3.52 X 1015

5 nm

1.0 X 1013

0.01

314

3.52 X 1015

20 nm

7.0 X 1011

0.05

5024

3.52 X 1015
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Table II.
HPLC Peak Areas of BSA AGEs generated under incubation condition
with or without different sizes of GNP in experiment A
UV Absorbance at 280nm

BSA+D-Ribose
with 2nm GNP

BSA+D-Ribose
with 5nm GNP

BSA+D-Ribose
with 20nm GNP

BSA+D-Ribose
without GNP

Fluorescence Intensity
(Excitation: 340nm Emission: 420nm)

Peak1 and 2

Peak 3

Peak 1

Peak2

87.227

151.948

22.099

374.429

Peak1 and 2

Peak 3

Peak 1

Peak 2

82.097

138.390

12.347

346.101

Peak1 and 2

Peak 3

Peak 1

Peak 2

88.782

173.654

44.230

435.874

Peak1 and 2

Peak 3

Peak 1

Peak 2

258.626

316.672

144.484

502.327
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Table III.
Mass Shift of BSA glycated by D-ribose with or without the presence of
GNP in experiment A
Peak m/z value
(double charge)

Glycated BSA shifted
m/z
(double charge)

Approximate number of
D-ribose adducts

BSA Blank

33100

0

0

BSA +D-Ribose

39100

6000

80

37170

4070

54

36980

3800

50

37780

4680

62

BSA+D-Ribose+ 2nm
GNP
BSA+D-Ribose+ 5nm
GNP
BSA+D-Ribose+ 20nm
GNP

130

Manuscript 4
Prepared for Analytical Biochemistry
Anticipated submission date: February, 2013

Ultraviolet C radiation enhances glycation of human serum
albumin and the formation of CML in vitro
Weixi Liu 1, Menashi A. Cohenford 2, Leslie Frost 3, Joel A. Dain 1*

1

Department of Chemistry, University of RI, Kingston, RI 02881
Department of Integrated Science and Technology, Marshall University, Huntington,
WV 25755
3
Department of Chemistry, Marshall University, Huntington, WV 25755
2

E-mail address: wliu@chm.uri.edu (Weixi Liu).
E-mail address: cohenford@marshall.edu (Menashi A. Cohenford).
E-mail address: frost@marshall.edu (Frost Leslie)
*Corresponding author: Phone: + 1-401-874-5942; fax: + 1-401-874-5072
E-mail address: jdain@chm.uri.edu (Joel A. Dain).

131

Abstract:
Non-enzymatic glycation of human serum albumin (HSA) is a major
contributor to the pathology of diabetes. The final products of this reaction
are a polymorphic group of compounds collectively referred to as Advanced
Glycation Endproducts (AGEs). Exposure to ultraviolet C (UVC) irradiation is
known to perturb protein structure and generate reactive oxygen species
(ROS) such as hydrogen peroxides, which might eventually accelerate
protein glycation and enhance the formation of AGEs. The objective of this
study was to evaluate the effect of UVC irradiation on the glycation level of
human serum albumin and the formation of carboxymethyl lysine (CML), a
well characterized AGE which is used as a biomarker of oxidatively
damaged tissues in vivo. A combination of several analytical methods
including UV spectrometry, HPLC and MALDI-TOF were used to study the
glycation level of HSA at 37 °C under neutral pH in the presence of
D-glucose in vitro. Compared to the untreated HSA, UVC exposed HSA
showed a more rapid increase in absorbance intensity at 280 nm over time,
as well as enhanced peak areas of AGEs in the HPLC elution profile. In
MALDI-TOF spectrum, more D-glucose adducts were found on UVC treated
HSA, generating a higher mass shift of protein. We also quantified the
amount of CML using enzyme-linked immunosorbent assay technique with a
monoclonal antibody which recognizes CML. Comparing to control samples
in the dark, reactions exposure to UVC radiation produced about double
132

amount of CML within 48 hours of incubation. In conclusion, exposure to
UVC radiation accelerates the glycation level of HSA and promotes the
formation of AGEs, which may be stimulated by the generation of ROS by
UV radiation. This study warrants further investigation as there have been
few reports on the correlation between the UV radiation of proteins and their
enhanced glycation by a reducing sugar.
Key words: HSA, CML, glycation, UVC, ROS
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1. Introduction
Human serum albumin (HSA) constitutes almost half of the protein
content in the plasma of normal healthy individuals [1]. As one of the major
circulating protein in blood, HSA is the most abundant protein and utilizes a
wide variety of physiological functions due to the flexibility of its structure [2].
First of all, albumin has a comparatively low molecular weight of 66 KDa
comparing to other globulins in the plasma system. This property makes the
protein a key element in maintaining the osmotic pressure needed for
proper distribution of body fluids between intravascular compartments and
body tissues [3]. HSA also functions as a carrier protein for small size
metabolites such as hydrophobic steroid hormones, ions and fatty acids.
The binding sites which allow the affinity for these metabolites are
distributed widely on all three domains of the protein. As a result, albumin is
also involved in the pharmacokinetics of many therapeutic drugs that can be
bound to the protein [4, 5]. In addition, HSA represents the predominant
antioxidant in plasma, a body compartment continuously exposed to high
oxidative stress [6, 7]. Previous study has shown that more than 70% of the
free radical-trapping activity of serum was due to HSA [6].
In normal conditions, HSA has a long half-life time of about 21 days and
a high plasmatic concentration between 35 to 50 mg/ml. Being constantly
exposed to numerous metabolites, albumin is highly sensitive to the
structural modification by these molecules. In particularly, non-enzymatic
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glycation is among the major mechanisms which contribute to the alteration
of HSA’s functions. Glycation is a non-enzymatic process that involves a
series of steps initiated with a condensation reaction between the aldehyde
group of a reducing sugar and the free amino group of a protein, resulting in
the formation of an unstable aldimine, also known as the Schiff base. This
intermediate then undergoes Amadori rearrangement and converts to a
more stable ketoamine structure referred to as Amadori products. Late stage
of glycation involves irreversible modification of these early stage glycation
intermediates

such

as

dehydration,

cyclization,

oxidation,

and

rearrangement to form a polymorphic group of compounds called advanced
glycation endproducts (AGEs) [8-10]. The accumulation of AGEs plays a
significant role in the pathogenesis of diabetic complications.
Glycated albumin accounts for about 80% of the circulating glycated
protein [11]. In vivo, the proportion of glycated albumin in healthy persons is
in the range of between 1% and 10% [2]. In the case of diabetes mellitus, the
proportion of glycation HSA may increase two to three fold and even reach to
90% for severe diabetic patients with poor diabetic control [12, 13].
Glycation-induced modiﬁcations have a determinant impact on HSA’s
biological functional properties such as its antioxidant property and
metabolites binding capacity. In addition, glycation is accompanied by the
production of AGEs, which triggers the release of pro-inflammatory
molecules and free radicals, inducing oxidative cellular dysfunction.

135

The glycation level of HSA can be up-graded by several factors
including genetic deficiency, high calories diet and environmental factors.
UV light is electromagnetic radiation with a wavelength in the range of 100
nm to 400 nm. UV radiation is classified into three types or bands—UVA
(400-315 nm), UVB (315-280 nm), and UVC (280-100 nm). Exposure to
ultraviolet (UV) irradiation is known to perturb protein structure and generate
reactive oxygen species (ROS) [14, 15]. Solar UVC is absorbed by ozone in
the stratosphere and the biological effect on human beings from natural
sources is limited. However, with increasing use of man-made UVC radiation
such as germicidal application and light therapy for wound healing, there is a
growing concern about the biological effect of UVC. Previously study has
shown that UVC irradiation could disturb structural stability of HSA and
cause conformational rearrangement and aggregation of the protein [16].
The production of ROS was also found to be stimulated by UVC irradiation in
vivo [17].
ROS play a significant role in the mechanism of protein glycation. The
free radicals are not only the product of glycation, but can also accelerate the
reaction rate and enhance the formation of AGEs. This suggests that UVC
radiation might eventually promote protein glycation by disturbing structural
stability of HSA and producing ROS. The objective of this study was to
evaluate the effect of UVC irradiation on the glycation level of human serum
albumin when D-glucose was used as model glycator. The formation of
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carboxymethyl lysine (CML), a well characterized AGE which is used as a
biomarker of oxidatively damaged tissues was also measured. A
combination of several analytical methods including UV spectrometry, HPLC,
ELISA and MALDI-TOF were used to study the glycation level of HSA at
37 °C under neutral pH in the presence of D-glucose in vitro.

6 Materials and methods
6.1 Chemicals and supplies
Fatty acid free albumin from human serum (HSA) and analytical grade
D-glucose were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO,
USA). Disposable UV-transparent cuvettes (12.5 mm X12.5 mm X 36 mm)
and HPLC analytical grade solvents were obtained from Thermo Fisher
Scientific (Rockford, IL, USA). Ziptip pipette tips with C4 resin and 0.22 µm
filter unit were purchased form EMD Millipore Co. (Billerica, MA, USA).
Photometric Enzyme-Linked Immunosorbent Assay (ELISA) kit for the
quantitative determination of Carboxymethyl Lysine (CML) was purchased
from Neo Bio Lab (Cambridge, MA, USA). Unless otherwise indicated, all
other reagents of analytical grade were purchased from Sigma-Aldrich
Chemical Co. (St. Louis, MO, USA).
6.2 Sample preparation and UVC exposition
Stock solutions of HSA (105 mg/ml) and D-glucose (100 mM) were
prepared in 0.1 M phosphate buffer, pH 7.2. Blank solutions included 35
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mg/ml HSA alone or 20 mM D-glucose alone. Controls included 35 mg/ml
BSA incubated with 20 mM D-glucose incubated in dark without any
exposure to UVC radiation. The concentration of HSA was adjusted to 35
mg/ml because this is the reported serum albumin concentration in health
human individuals. The concentration of D-glucose was adjusted to 20 mM,
the concentration reported to be the blood sugar content under diabetic
condition. Two sets of studies were conducted designated as experiment A
and experiment B.
In experiment A, 35 mg/ml HSA incubated with 20 mM D-glucose in 0.1
M phosphate buffer at 37 °C, pH 7.2 for up to 14 days. Reaction mixture
incubated in dark without any exposure to UVC radiation was serving as
control solution. Experiment group was exposed to UVC light with a peak
wavelength at 254 nm. The UVC radiation was produced by a 30 watts
low-pressure vapor discharge lamp.
In experiment B, HSA was exposed to UVC light for 24 hours before the
glycation agent was added into the solution. In control group, 35 mg/ml HSA
was incubated in dark at 37 °C for 24 hours and then mixed with 20 mM
D-glucose. In comparison, experiment solution was prepared by first
exposing 35 mg/ml HSA under UVC light with a peak wavelength at 254 nm
for 24 hours, then mixing with 20 mM D-glucose. Both control and
experiment samples were then incubate in dark at 37 °C for up to 96 hours.
After incubation, all reaction mixtures were placed at -20 °C until analyzed.
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Prior analysis, all samples were unfrozen, ultra-centrifuged at 5X103 rpm for
15 min and the supernates were further purified by ZipTip pipette with C4
resin.
2.3 UV spectroscopy
UV readings were obtained at a wavelength of 280 nm with an
UltroSpec 2100 instrument (Biochrom Ltd, Cambridge, UK). The above
wavelength was determined optimal for detecting HSA AGEs by spectrum
scan ranging from 200 nm to 400 nm. All samples were diluted 20 fold before
analysis and all readings were obtained in thermostatically controlled
cuvettes that were maintained at 25±1 °C. All values are the average of
triplicate measurements.
2.4 High-performance liquid chromatography
Each HPLC run was performed in triplicate using a Hewlett Packard
1050 system (Waldbronn, Germany) equipped with a low-pressure gradient
pump, a four-channel degasser, a sequential auto sampler, a high sensitivity
diode-array detector (190–800 nm) and a programmable fluorescence
detector (HP 1046A). The HPLC system was operated with the ChemStation
System from Agilent Technologies (Santa Clara, CA, USA) with the same
software used also for data analysis. AGE species were separated on a
Shodex (New York, NY, USA) RSpak C18 reverse phase HPLC column (5
μm×4.6 mm×150 mm) with 415 Å pore size. Mobile phase A consisted of 0.1%
trifluoroacetic acid (TFA) in water and mobile phase B consisted of 0.1%
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TFA in ACN. A linear gradient from 20% to 60% of mobile phase B was
applied in 20 minutes at a constant flow rate of 1.0 ml/min. Prior to HPLC
analysis, all solvents were degassed and sonicated for 15 min. All samples
were filtered with a 0.22 μm membrane, degassed and centrifuged.
2.5 ELISA with anti-CML AGE antibodies
ELISA assay was performed according to the standard procedure
provided by Neo Bio lab form where the ELISA assay kit (Catalog Number:
PC0780) was obtained. Each sample was first diluted 10 times to 100 µl and
then added to the labeled wells in the supplied microtiter plate. Then 50 µl of
conjugate solution was added in each well and the plate was covered and
incubated for 1 hour at 37 °C. Each well was washed for 5 times with
300-400 µl wash solution followed by the addition of 50 µl substrate A to
each well and then 50 µl substrate B. The plate was again covered and put
into incubation for 15 minutes at room temperature. Finally, 50 ul of stop
solution was added to each well and the optical density (O.D.) for each
sample was immediately determined at 450 nm using a Spectra Max M2
spectrometer (Molecular Devices, Sunnyvale, CA). Each experiment
solution was run in duplicate and the values were averaged.
2.6 Preparation and analysis of intact HSA by MALDI-TOF MS
All samples were purified with C4 ZipTips and analyzed on a Bruker
Autoflex MALDI–TOF (time-of-flight) mass spectrometer (Bruker Daltonics,
Billerica, MA, USA). Prior to analysis, the protein samples (0.6 μl) were
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mixed with a 50% aqueous acetonitrile solution (0.6 μl) of saturated sinapinic
acid containing 0.05% trifluoroacetic acid (TFA) as matrix, spotted onto a
stainless steel sample plate, and allowed to air dry. Spectra were acquired in
linear TOF mode with a 550 ns delay in the m/z range from 20,000 to 80,000.
Each spectrum was the sum of 500 single laser shots randomized over 10
positions within the same spot (500/50). Analysis of data was performed
using FlexAnalysis and ClinProTools (Bruker Daltonics).

3 Results
3.1 Detection of aromatic AGEs by UV spectrometry
Tables I shows the UV absorption readings of incubation mixtures
containing 35 mg/ml HSA with 20 mM D-glucose (hereinafter referred to as
“HSA-glc”) in both experiment A and B. In experiment A, samples were
collected at different time points (0, 1, 2, 4 and 7 days of incubation
respectively). In both control sample which was incubated in dark and
experimental sample which was exposed to constant UVC radiation, HSA
was found to form AGEs and the highest levels of glycation were achieved
when HSA reacted with D-glucose for 7 days. It should be noted that a
severe protein crosslinking was observed in UV exposed sample after 7
days incubation. HSA denatured and precipitated out of phosphate buffer
due to protein conjugation. As a result, only samples collected within the first
7 days of reaction were analyzed afterwards. A considerable difference in
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UV intensities between control sample and UVC treated sample revealed
that exposure to UVC radiation enhanced the glycation level of HSA. The
formation of aromatic AGEs which exhibited a UV absorbance at 280 nm
was boosted by UVC treatment, producing a UV intensity value (λ280=1.172)
almost double as the untreated HSA-glc mixture (λ280=0.623) after 7 days
incubation. No increases were observed in the UV absorbance of blanks
containing HSA alone. Similarly, no increases in the UV absorbance of
control tubes containing freshly added HSA with D-glucose were noted. In
experiment B, HSA was pre-incubated under the exposure of UVC radiation
before D-glucose was added to the solution. A close scrutiny of the UV
values in table I revealed that comparing to control, the rate and extent of
glycation in UVC treated sample were much higher even at the initially stage
of the reaction after 24 hours incubation, yielding an intensity value
(λ280=1.322) almost four times higher than the untreated solution
(λ280=0.091). Similar to experiment A, HSA started to form cross-linked
structures and precipitated out of the mixture after 96 hours incubation. As a
result, only samples collected within the first 96 hours of reaction in
experiment B were analyzed afterwards. The UV readings obtained at 280
nm revealed two important findings: 1) UVC radiation enhanced the
formation of aromatic AGEs of HSA, which was found to be responsible for
the increased UV intensity at 280 nm; 2) HSA exposed to UVC radiation was
more prone to be glycated by reducing sugar. This finding suggested that
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UVC treatment might cause conformational restructuring of HSA, making the
protein more susceptible to glycation.
3.2 Quantification of AGEs by HPLC
The extent of HSA glycation under the treatment of UVC radiation in
both experiment A and B was determined by HPLC. Figure 1 shows the
HPLC elution profile of blank solution of HSA alone and control solutions of
HSA freshly added to D-glucose. Protein alone eluted as one prominent
peak with a retention time (Rt) of 14.02 min. Under the same separation
conditions, freshly mixed solutions of HSA with D-glucose also yielded one
discrete peak coincident in location with that of HSA (Rt=14.02 min). This
control showed that immediate mixing of the sugar with HSA had no effect on
the elution profile of HSA itself; nor did it immediately cause the formation of
AGEs.
Figure 2 and figure 3 show the HPLC elution profiles of HSA-glc mixture
incubated in dark (figure 2) or incubated under the exposure to UVC
radiation (figure 3) for 2 days in experiment A. A series of new peaks that
emerged represent the formation of several AGE species in both solutions.
According to the peak area intensities of these glycation products numbered
peak 1 (Rt=1.87 min), peak 2 (Rt=3.15 min) and peak 3 (5.10 min),
experimental sample under UVC radiation yielded AGE peaks with higher
band areas comparing to that of control solution incubated in dark (data
shown in Table II). Meanwhile, the peak area of band eluted at 14.02 min
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which represented unglycated HSA had a lower value than HSA peak in
control mixture; indicating HSA had been modified by D-glucose more
intensively to form AGEs when treated by UVC. HPLC Elution profiles of
HSA-glc mixture incubated for 7 days were shown in figure 4 (control
solution incubated in dark) and figure 5 (experimental solution incubated
under UVC radiation). Again, three AGE species were observed in both
profiles. However, the amount of unglycated HSA was drastically decreased
comparing to that of control, yielding a peak intensity of only 715.3. In the
meanwhile, the peak area of AGE eluted as peak number 1 in UV treated
sample was much higher than that of the solution incubated in dark,
revealing a higher glycation level.
Figure 8 and 9 show the HPLC elution profiles of reaction mixtures in
experiment B after 48 hours incubation. Incubations of UVC-treated HSA
with D-glucose yielded four additional peaks numbered 1, 2, 3, and 4 with
retention times of 1.71 min, 1.87 min, 3.14 min and 5.08 min respectively
(seen in figure 9). Whereas profile of untreated HSA incubated with
D-glucose for 48 hours indicated the formation of only three AGE species
formed, a result indicated that more AGE species were formed when HSA
was pre-treated with UVC radiation for 24 hours. Moreover, the peak
intensity of AGE species in UVC treated solution was higher than the value
of untreated control sample, verifying that exposure to UVC radiation made
HSA more susceptible to glycation by reducing sugar.
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3.3 The detection of CML by ELISA
CML is an AGE resulted from oxidative stress and chemical glycation.
CML adducts was found accumulated with aging and over produced in
several

diabetic

related

complications.

CML-modified

proteins

are

recognized by the receptor RAGE which is expressed on a variety of cells.
This process could initiate the expression of ROS and induce oxidative
stress. The formations of CML in HSA-glc mixtures in both experiment A and
B were evaluated by ELISA assy. Higher levels of CML leaded to increased
CML-antibody conjugate binding and greater OD signal at 450 nm. Figure 10
shows the OD intensities of reaction mixtures in experiment A including a) 35
mg blank HSA, b) HSA-glc incubated in dark and c) HSA-glc incubated
under UVC radiation. The increased in OD value over time revealed the
formation of CML in both mixture b and c over time. No OD absorbance at
450 nm was observed when HSA was incubated along without any glycation
agent. Comparing to sample incubated in dark, UVC treated solution
produced a much higher amount of CML and the highest CML level was
observed in HSA-glc mixture incubated under UVC radiation for 7 days. In
experiment B, HSA pre-treated by UVC radiation yielded more CML
comparing to untreated HSA (showing in figure 11). The difference in CML
levels between control solution and UVC exposed sample started to be
observed at the very early stage of glycation after only 12 hours of incubation.
After 48 hours, UVC treated HSA produced about double amount of CML
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comparing to control solution, an observation confirming our earlier
conclusion base on UV spectrometry and HPLC elution profile.
3.4 Measurement of HSA mass shift by MALDI-TOF
To determine the number of sugar addicts on HSA forming by glycation,
we used MALDI-TOF to quantify the mass shift of glycated HSA comparing
to unglycated BSA. Since the increase in m/z value was mainly due to the
addict of D-glucose molecules to the protein, the approximate number of
sugar adducts on glycated HSA in each incubation mixture can be calculated
based on the shift in m/z value (shown in table III). A greater number of sugar
addicts on protein revealed a higher extent of glycation, resulting in an
enhanced formation of AGEs. It should be noted that each MALDI spectra
shown in figure 12 to figure 18 reflected the double charged albumin
molecule which gave a better spectrum peak in each profile. As a result, the
actual mass value for glycated HSA should be doubled by the m/z value
obtained in MALDI spectrum.
A close scrutiny of the table confirmed the earlier observations that the
extent of HSA was enhanced by exposing sample to UVC radiation. Solution
containing HSA alone showed m/z value of 33000 Da in double charged
form, resulting in a protein mass of 66000 Da which is closed to the reported
HSA molecule weight. Based on the mass shift, the glycation levels of
reaction mixtures in experiment A were not very considerable after 2 days
incubation. In solution incubated in dark, one D-glucose addict was found on

146

HSA after 2 days reaction and two sugar molecules were found to addict on
HSA in UVC treated sample. The difference was enhanced by prolonging the
incubation time to 7 days. In samples incubated for 7 days, we noticed a
mass shift of 740 in solution exposed to UVC radiation, which equals to 8
D-glucose addicts, whereas only 3 sugar molecules were found to addict on
HSA in mixture incubated in dark. This observation again corresponded to
our early conclusion that UVC irradiation enhanced the degree of glycation.
Moreover, HSA pre-incubated under UVC radiation for 24 hours in
experiment B yielded mass shift of 290 after 48 hours incubation, which
equals to 3 D-glucose addicts on HSA. Interestingly, this number is closed to
the mass shift produced by HSA-glc mixture incubated in dark for 7 days,
which suggested that the exposure to UVC not only enhanced the glycation
level, but also increased the reaction rate.

4. Conclusion
The non-enzymatic glycation of HSA has been found to play a major role
in human physiology. The reactive carbonyl groups of reducing sugars
condensed with the amino groups of certain amino acid residues such as
lysine and arginine on HSA and form Amadori products that can rearrange to
form AGEs after a variety of chemical reactions. Accumulation of AGEs has
been reported to account for many of the chronic complications including
diabetes and Alzheimer’s disease.
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Recently, there has been an increasing interest on the physiological
effect of UVC radiation since they are readily absorbed by DNA and are
highly genotoxic [19]. The biological effects of ultraviolet radiation (UV)
include DNA damage, mutagenesis, cellular aging, and carcinogenesis.
These effects are in part mediated by reactive oxygen species (ROS), the
production of which is stimulated by UV irradiation of cells and tissues [16,
18]. Since the production of ROS also enhanced the glycation level in
biological system, current study made an effort to evaluate the influence of
UVC radiation on the formation of AGEs when physiological concentration of
HSA was glycated by D-glucose in-vitro.
A combination of several analytical methods including UV spectrometry,
HPLC and MALDI-TOF revealed that UVC radiation enhanced the glycation
level of HSA even at the early stage of the reaction. Moreover, the glycation
rate was also boosted when the reaction took place under UVC exposure.
HSA started to form noticeable cross-link structures after a few days
treatment with UVC, denaturized, and precipitated out from the reaction
system. HSA pre-incubated under UVC radiation was more susceptible to
glycation by reducing sugar comparing to untreated HSA. Although the
detailed mechanism of this phenomenon is still under elucidation, it might be
related to the alteration in HSA’s conformational structure when the protein is
exposed to UVC radiation.
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In this study we also quantified the production of CML from HSA
glycation using ELISA immune assay. The major source of CML during
protein glycation is oxidative degradation of Amadori intermediate and ROS
was found to accelerate the formation of CML. We observed a considerable
increase in CML production when the protein was glycated under UVC
radiation; a finding suggested that UVC radiation promoted the formation of
ROS, which could then stimulate oxidative degradation of Amadori addicts to
form AGEs.
At present, there is little information on the biological effect of short UV
wavelength, and there is practically no data on glycation of HSA under the
influence of UVC radiation. UVC radiation was found to enhance the
glycation rate and promote the formation of HSA AGEs. The high energy UV
radiation was also suspected to perturb protein structure; making protein
more susceptible to glycation. As a result, more attention on the safe usage
of UVC light should be addressed because the negative biological effect of
high energy, short wavelength UV may not only be related to their genotoxic
but may also be caused by their ability to enhanced protein glycation.
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Figure 1. HPLC-UV elution profile of 35 mg/ml HSA alone in 0.1 M
phosphate buffer, pH 7.2 serving as blank solution. HSA eluted at 14.02
minute, producing a single peak with a total peak area of 1402.6.
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Figure 2. HPLC-UV elution profile of control reaction mixture containing 35
mg/ml HSA and 20 mM D-glucose in experiment A. The sample was
incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 2 days before
analysis.
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Figure 3. HPLC-UV elution profile of experimental reaction mixture
containing 35 mg/ml HSA and 20 mM D-glucose in experiment A. The
sample was incubated in 0.1 M phosphate buffer, pH 7.2 under UVC
radiation for 2 days before analysis.
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Figure 4. HPLC-UV elution profile of control reaction mixture containing 35
mg/ml HSA and 20 mM D-glucose in experiment A. The sample was
incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 7 days before
analysis.
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Figure 5. HPLC-UV elution profile of experimental reaction mixture
containing 35 mg/ml HSA and 20 mM D-glucose in experiment A. The
sample has been incubated in 0.1 M phosphate buffer, pH 7.2 under UVC
radiation for 7 days before analysis.
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Figure 6. HPLC-UV elution profile of control reaction mixture containing 35
mg/ml HSA and 20 mM D-glucose in experiment B. HSA was pre-incubated
in dark for 24 hours before D-glucose was added. The sample was then
incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 48 hours before
analysis.
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Figure 7. HPLC-UV elution profile of experimental reaction mixture
containing 35 mg/ml HSA and 20 mM D-glucose in experiment B. HSA was
pre-incubated under UVC exposure for 24 hours before D-glucose was
added. The sample was then incubated in 0.1 M phosphate buffer, pH 7.2 in
dark for 2 days before analysis.
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Figure 8. Modified HPLC-UV elution profile of spectrum shown in figure 6.
Unglycated HSA with a retention time of 14.02 minute was eliminated in the
spectrum to improve the view of AGE signals.
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Figure 9. Modified HPLC-UV elution profile of spectrum shown in figure 7.
Unglycated HSA with a retention time of 14.02 minute was eliminated in the
spectrum to improve the view of AGE signals.
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Figure 10. Comparison of the production of CML in each reaction mixture in
experiment A with incubation times of 0, 2 and 7 days. The amount of CML
was detected with antibodies to glucose-modified HSA using ELISA assay.
The increase in OD value indicated the accumulation of CML over time.
Each experiment solution was run in duplicate and the values were
averaged.
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Figure 11. Comparison of the production of CML in each reaction mixture in
experiment B with incubation times of 12, 24 and 48 hours. The amount of
CML was detected with antibodies to glucose-modified HSA using ELISA
assay. The increase in OD value indicated the accumulation of CML over
time. Each experiment solution was run in duplicate and the values were
averaged.
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Figure 12. MALDI-TOF profile of reaction mixtures containing 35 mg/ml
HSA incubated in dark at 37 °C for 7 days. The spectrum peak indicates to
double charge intact HSA. The maximum peak m/z value was found at
33000.
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Figure 13. MALDI-TOF profile of reaction mixtures containing 35 mg/ml
HSA and 20 mM D-glucose incubated in dark at 37 °C for 2 days
(experiment A). The spectrum peak indicates to double charged glycated
HSA. The maximum peak m/z value was found at 33080.
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Figure 14. MALDI-TOF profile of reaction mixtures containing 35 mg/ml
HSA and 20 mM D-glucose incubated under UVC radiation at 37 °C for 2
days (experiment A). The spectrum peak indicates to double charged
glycated HSA. The maximum peak m/z value was found at 33180.
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Figure 15. MALDI-TOF profile of reaction mixtures containing 35 mg/ml
HSA and 20 mM D-glucose incubated in dark at 37 °C for 7 days
(experiment A). The spectrum peak indicates to double charged glycated
HSA. The maximum peak m/z value was found at 33280.
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Figure 16. MALDI-TOF profile of reaction mixtures containing 35 mg/ml
HSA and 20 mM D-glucose incubated under UVC radiation at 37 °C for 7
days (experiment A). The spectrum peak indicates to double charged
glycated HSA. The maximum peak m/z value was found at 33740.
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Figure 17. MALDI-TOF profile of reaction mixtures containing 35 mg/ml
HSA and 20 mM D-glucose (experiment B). HSA was pre-incubated in dark
for 24 hours before D-glucose was added. The sample was then incubated
in 0.1 M phosphate buffer, pH 7.2 in dark for 2 days before analysis. The
spectrum peak indicates to double charged glycated HSA. The maximum
peak m/z value was found at 33100.
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Figure 18. MALDI-TOF profile of reaction mixtures containing 35 mg/ml
HSA and 20 mM D-glucose (experiment B). HSA was pre-incubated under
UVC radiation for 24 hours before D-glucose was added. The sample was
then incubated in 0.1 M phosphate buffer, pH 7.2 in dark for 2 days before
analysis. The spectrum peak indicates to double charged glycated HSA.
The maximum peak m/z value was found at 33290.
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Table I
UV readings of reaction mixtures containing 35 mg/ml HSA and 20 mM
D-glucose incubated in dark or under UVC radiation

Experiment A

Incubation
Time

Experiment B

Dark

UV Exposure

Dark

UV Exposure

0d

0.000±0.01

0.000±0.001

0.000±0.002

0.000±0.001

1d

0.075±0.003

0.275±0.004

0.091±0.002

0.322±0.004

2d

0.287±0.005

0.459±0.002

0.290±0.003

0.507±0.005

4d

0.336±0.001

0.713±0.002

0.389±0.003

0.728±0.006

7d

0.523±0.006

1.172±0.004

N/A

N/A
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Table II.
HPLC Peak Areas of unglycated HSA and HSA AGEs generated with or without
the exposure to UVC radiation in experiment A (7 days) and B (48 hours)
Experiment A

Experiment B

AGE peak 1

314.7

AGE peak 1

65.5

AGE peak 2

12.1

AGE peak 2

121.1

AGE peak 3

72.7

AGE peak 3

50.6

dark (Control)

Unglycated
HSA

937.9

Unglycated
HSA
AGE peak 1

1168.6

AGE peak 1

541.6

AGE peak 2

15.3

AGE peak 3

125.8

AGE peak 3

78.4

AGE peak 4

63.0

and 2

128.9

UVC radiation
(Experimental)

Unglycated
HSA

715.3
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Unglycated
HSA

1051.9

Table III.
Mass Shift of HSA glycated by D-glucose in dark or under the exposure of UVC
radiation in experiment A and B
Incubation Condition

Peak m/z value

Glycated BSA shifted

Approximate number

m/z

of D-glucose

(double charge)

(m/z=180) adducts

(double charge)

Experiment A

HSA Blank
HSA + D-glucose in
dark (2 days)

33000

0

0

33080

80

1

33180

180

2

33280

280

3

33740

740

8

33000

0

0

33100

100

1

33290

290

3

HSA + D-glucose
under UVC
(2 days)
HSA + D-glucose in
dark (7 days)
HSA + D-glucose
under UVC
(7 days)
Experiment B

HSA Blank

HSA + D-glucose in
dark (48 hours)
HSA + D-glucose
under UVC
(48 hours)
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